section#	Drug_1_type	Drug_1_mention	Drug_1_annotation_agent	Drug_1_starting_offset	Drug_1_ending_offset	Drug_2_type	Drug_2_mention	Drug_2_annotation_agent	abbreviation_translation	Drug_2_start_offset	Drug_2_end_offset	DDI_modality	DDI_statement_type	snippit_of_DDI	
1	Active ingredient	tenofovir 	consensus set annotator team	367	376	Active ingredient	didanosine 	consensus set annotator team		318	328	Positive	Qualitative	Exposure to didanosine is increased 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	4165	4177	Metabolite	ODV 	consensus set annotator team	Venlafaxine 	4454	4457	Positive	Quantitative	AUC increased by 21% in EM subjects and 70% in PM subjects 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	4165	4177	Active ingredient	Venlafaxine 	consensus set annotator team		4335	4346	Positive	Quantitative	AUC increased by 21% in EM subjects and 70% in PM subjects 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	4165	4177	Metabolite	ODV 	consensus set annotator team	Venlafaxine 	4268	4271	Positive	Quantitative	Cmax increased by 26% in EM subjects and 48% in PM subjects 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	4165	4177	Active ingredient	Venlafaxine 	consensus set annotator team		4179	4190	Positive	Quantitative	Cmax increased by 26% in EM subjects and 48% in PM subjects 	consensus set annotator team
5	Active ingredient	lithium 	consensus set annotator team	2456	2463	Metabolite	ODV 	consensus set annotator team	venlafaxine 	2510	2513	Negative	Qualitative	no effect on the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	6788	6799	Active ingredient	risperidone 	consensus set annotator team		7056	7067	Positive	Quantitative	32% increase in risperidone AUC 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	5761	5772	Metabolite	?-hydroxymetoprolol 	consensus set annotator team	metoprolol 	6097	6116	Negative	Qualitative	without altering the plasma concentrations of its active metabolite, ?-hydroxymetoprolol 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	5761	5772	Active ingredient	metoprolol 	consensus set annotator team		5990	6000	Positive	Quantitative	an increase of plasma concentrations of metoprolol by approximately 30 to 40% 	consensus set annotator team
5	Active ingredient	Imipramine 	consensus set annotator team	5572	5582	Metabolite	ODV 	consensus set annotator team	venlafaxine 	5638	5641	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Imipramine 	consensus set annotator team	5572	5582	Active ingredient	venlafaxine 	consensus set annotator team		5622	5633	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	5499	5510	Metabolite	2-OH-desipramine 	consensus set annotator team	imipramine 	5439	5455	Positive	Quantitative	AUC's increased by at least 2.5 fold (with venlafaxine 37.5 mg q12h) and by 4.5 fold 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	5422	5433	Active ingredient	desipramine 	consensus set annotator team		5348	5359	Positive	Quantitative	AUC, Cmax, and Cmin increased by about 35% 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	5256	5267	Metabolite	2-OH-imipramine 	consensus set annotator team	imipramine 	5322	5337	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	7861	7872	Active ingredient	caffeine 	consensus set annotator team		8033	8041	Negative	Qualitative	did not inhibit the metabolism 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	11366	11377	Active ingredient	clozapine 	consensus set annotator team		11247	11256	Positive	Qualitative	reports of elevated clozapine levels 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	8073	8084	Active ingredient	tolbutamide 	consensus set annotator team		8231	8242	Negative	Quantitative	did not alter the pharmacokinetics 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	7370	7381	Active ingredient	terfenadine 	consensus set annotator team		7479	7490	Negative	Qualitative	did not inhibit the metabolism 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	7370	7381	Active ingredient	diazepam 	consensus set annotator team		7465	7473	Negative	Qualitative	did not inhibit the metabolism 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	7370	7381	Active ingredient	alprazolam 	consensus set annotator team		7453	7463	Negative	Qualitative	did not inhibit the metabolism 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	7082	7093	Active ingredient	risperidone 	consensus set annotator team		7195	7206	Negative	Qualitative	did not significantly alter the pharmacokinetic profile of the total active moiety 	consensus set annotator team
5	Active ingredient	Indinavir 	consensus set annotator team	7728	7737	Metabolite	ODV 	consensus set annotator team	venlafaxine 	7793	7796	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Indinavir 	consensus set annotator team	7728	7737	Active ingredient	venlafaxine 	consensus set annotator team		7777	7788	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	2535	2546	Active ingredient	lithium 	consensus set annotator team		2588	2595	Negative	Qualitative	no effect on the pharmacokinetics 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	3872	3884	Active ingredient	venlafaxine 	consensus set annotator team		3921	3932	Positive	Qualitative	resulted in higher plasma concentrations 	consensus set annotator team
5	Active ingredient	venlafaxine 	consensus set annotator team	2187	2198	Active ingredient	haloperidol 	consensus set annotator team		2131	2142	Positive	Quantitative	Cmax increased 88 	consensus set annotator team
5	Active ingredient	ketoconazole 	consensus set annotator team	3872	3884	Metabolite	O-desmethylvenlafaxine 	consensus set annotator team	venlafaxine 	4091	4113	Positive	Qualitative	resulted in higher plasma concentrations 	consensus set annotator team
5	Active ingredient	ethanol 	consensus set annotator team	51	58	Metabolite	O-desmethylvenlafaxine 	consensus set annotator team	venlafaxine 	126	148	Negative	Qualitative	no effect on the pharmacokinetics 	consensus set annotator team
5	Active ingredient	diazepam 	consensus set annotator team	1556	1564	Active ingredient	venlafaxine 	consensus set annotator team		1493	1504	Negative	Qualitative	did not appear to affect the pharmacokinetics 	consensus set annotator team
5	Active ingredient	cimetidine 	consensus set annotator team	487	497	Active ingredient	venlafaxine 	consensus set annotator team		502	513	Positive	Qualitative	resulted in inhibition of first-pass metabolism 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	8312	8323	Active ingredient	diazepam 	consensus set annotator team		8358	8366	Negative	Qualitative	did not inhibit the metabolism 	consensus set annotator team
5	Active ingredient	cimetidine 	consensus set annotator team	487	497	Active ingredient	venlafaxine 	consensus set annotator team		662	673	Positive	Quantitative	the exposure (AUC) and maximum concentration (Cmax) of the drug were increased by about 60 	consensus set annotator team
5	Active ingredient	cimetidine 	consensus set annotator team	826	836	Metabolite	ODV 	consensus set annotator team	venlafaxine 	887	890	Negative	Qualitative	no apparent effect on the pharmacokinetics 	consensus set annotator team
5	Active ingredient	ethanol 	consensus set annotator team	51	58	Active ingredient	venlafaxine 	consensus set annotator team		111	122	Negative	Qualitative	no effect on the pharmacokinetics 	consensus set annotator team
5	Active ingredient	Metoprolol 	consensus set annotator team	6118	6128	Active ingredient	venlafaxine 	consensus set annotator team		6174	6185	Negative	Qualitative	did not alter the pharmacokinetic profile 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	1881	1892	Active ingredient	haloperidol 	consensus set annotator team		2131	2142	Positive	Quantitative	Cmax increased 88 	consensus set annotator team
5	Active ingredient	lithium 	consensus set annotator team	2456	2463	Active ingredient	venlafaxine 	consensus set annotator team		2365	2376	Negative	Qualitative	pharmacokinetics of venlafaxine administered at 150 mg/day were not affected 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	1881	1892	Active ingredient	haloperidol 	consensus set annotator team		2041	2052	Positive	Quantitative	resulted in a 70% increase in haloperidol AUC 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	1669	1680	Active ingredient	diazepam 	consensus set annotator team		1737	1745	Negative	Qualitative	did not have any effect 	consensus set annotator team
5	Active ingredient	Metoprolol 	consensus set annotator team	6118	6128	Metabolite	O-desmethylvenlafaxine 	consensus set annotator team	venlafaxine 	6212	6234	Negative	Qualitative	did not alter the pharmacokinetic profile 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	1669	1680	Metabolite	desmethyldiazepam 	consensus set annotator team	diazepam 	1772	1789	Negative	Qualitative	did not have any effect 	consensus set annotator team
5	Active ingredient	diazepam 	consensus set annotator team	1556	1564	Active ingredient	venlafaxine 	consensus set annotator team		1621	1632	Negative	Qualitative	did not appear to affect the pharmacokinetics of either venlafaxine or ODV 	consensus set annotator team
5	Active ingredient	diazepam 	consensus set annotator team	1556	1564	Metabolite	ODV 	consensus set annotator team	venlafaxine 	1636	1639	Negative	Qualitative	did not appear to affect the pharmacokinetics of either venlafaxine or ODV 	consensus set annotator team
5	Active ingredient	Venlafaxine 	consensus set annotator team	5256	5267	Active ingredient	imipramine 	consensus set annotator team		5307	5317	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	Amitriptyline 	consensus set annotator team	534	547	Metabolite	9-hydroxyrisperidone 	consensus set annotator team	risperidone 	618	638	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	ranitidine 	consensus set annotator team	696	706	Active ingredient	risperidone 	consensus set annotator team		740	751	Positive	Quantitative	increased the bioavailability of risperidone by 64% and 26 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	4342	4353	Active ingredient	galantamine 	consensus set annotator team		4421	4432	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	3315	3326	Active ingredient	erythromycin 	consensus set annotator team		3331	3343	Negative	Qualitative	There were no significant interactions 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	1278	1289	Active ingredient	valproate 	consensus set annotator team		1391	1400	Negative	Qualitative	did not affect the pre-dose or average plasma concentrations and exposure (AUC 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	1582	1593	Active ingredient	valproate 	consensus set annotator team		1503	1512	Positive	Quantitative	there was a 20% increase in valproate peak plasma concentration (Cmax 	consensus set annotator team
7	Active ingredient	Risperidone 	consensus set annotator team	1609	1620	Active ingredient	digoxin 	consensus set annotator team		1712	1719	Negative	Qualitative	did not show a clinically relevant effect on the pharmacokinetics 	consensus set annotator team
7	Active ingredient	Amitriptyline 	consensus set annotator team	534	547	Active ingredient	risperidone 	consensus set annotator team		587	598	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	ranitidine 	consensus set annotator team	883	893	Active ingredient	risperidone 	consensus set annotator team		915	926	Positive	Quantitative	increased the AUC of risperidone and 9-hydroxyrisperidone combined by 20% 	consensus set annotator team
7	Active ingredient	phenobarbital 	consensus set annotator team	3852	3865	Active ingredient	risperidone 	consensus set annotator team		3872	3883	Positive	Qualitative	may cause similar decreases in the combined plasma concentrations 	consensus set annotator team
7	Active ingredient	rifampin 	consensus set annotator team	3838	3846	Active ingredient	risperidone 	consensus set annotator team		3872	3883	Positive	Qualitative	may cause similar decreases in the combined plasma concentrations 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	4342	4353	Active ingredient	galantamine 	consensus set annotator team		4421	4432	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	4342	4353	Active ingredient	donepezil 	consensus set annotator team		4407	4416	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
7	Active ingredient	Carbamazepine 	consensus set annotator team	3392	3405	Metabolite	9-hydroxyrisperidone 	consensus set annotator team	risperidone 	3492	3512	Positive	Quantitative	decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50% 	consensus set annotator team
7	Active ingredient	Carbamazepine 	consensus set annotator team	3392	3405	Active ingredient	risperidone 	consensus set annotator team		3476	3487	Positive	Quantitative	decreased the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone by about 50% 	consensus set annotator team
7	Active ingredient	phenytoin 	consensus set annotator team	3827	3836	Active ingredient	risperidone 	consensus set annotator team		3872	3883	Positive	Qualitative	may cause similar decreases in the combined plasma concentrations 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	3476	3487	Active ingredient	carbamazepine 	consensus set annotator team		3552	3565	Negative	Quantitative	concentrations of carbamazepine did not appear to be affected 	consensus set annotator team
7	Active ingredient	Fluoxetine 	consensus set annotator team	2798	2808	Metabolite	9-hydroxyrisperidone 	consensus set annotator team	risperidone 	2852	2872	Negative	Qualitative	did not affect the plasma concentration 	consensus set annotator team
7	Active ingredient	paroxetine 	consensus set annotator team	2653	2663	Active ingredient	risperidone 	consensus set annotator team		2739	2750	Positive	Quantitative	increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold 	consensus set annotator team
7	Active ingredient	Paroxetine 	consensus set annotator team	2874	2884	Metabolite	9-hydroxyrisperidone 	consensus set annotator team	risperidone 	2914	2934	Positive	Quantitative	lowered the concentration of 9-hydroxyrisperidone by about 10% 	consensus set annotator team
7	Active ingredient	Cimetidine 	consensus set annotator team	681	691	Active ingredient	risperidone 	consensus set annotator team		740	751	Positive	Quantitative	increased the bioavailability of risperidone by 64% and 26 	consensus set annotator team
7	Active ingredient	Fluoxetine 	consensus set annotator team	2619	2629	Active ingredient	risperidone 	consensus set annotator team		2739	2750	Positive	Quantitative	increase the plasma concentration of risperidone 2.5 to 2.8 fold and 3 to 9 fold 	consensus set annotator team
7	Active ingredient	clozapine 	consensus set annotator team	1011	1020	Active ingredient	risperidone 	consensus set annotator team		1026	1037	Positive	Qualitative	may decrease the clearance 	consensus set annotator team
7	Active ingredient	risperidone 	consensus set annotator team	1118	1129	Active ingredient	lithium 	consensus set annotator team		1223	1230	Negative	Qualitative	did not affect the exposure (AUC) or peak plasma concentrations (Cmax 	consensus set annotator team
8	Active ingredient	phenobarbital 	consensus set annotator team	5198	5211	Active ingredient	risperidone 	consensus set annotator team		5218	5229	Positive	Qualitative	may cause a decrease in the combined plasma concentrations 	consensus set annotator team
8	Active ingredient	rifampin 	consensus set annotator team	5184	5192	Active ingredient	risperidone 	consensus set annotator team		5218	5229	Positive	Qualitative	may cause a decrease in the combined plasma concentrations 	consensus set annotator team
8	Active ingredient	phenytoin 	consensus set annotator team	5173	5182	Active ingredient	risperidone 	consensus set annotator team		5218	5229	Positive	Qualitative	may cause a decrease in the combined plasma concentrations 	consensus set annotator team
8	Active ingredient	carbamazepine 	consensus set annotator team	5158	5171	Active ingredient	risperidone 	consensus set annotator team		5218	5229	Positive	Qualitative	may cause a decrease in the combined plasma concentrations 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	3105	3116	Active ingredient	lorazepam 	consensus set annotator team		3197	3206	Negative	Qualitative	no significant pharmacokinetic interaction 	consensus set annotator team
9	Active ingredient	ethanol 	consensus set annotator team	3578	3585	Active ingredient	fluvoxamine 	consensus set annotator team		3675	3686	Negative	Qualitative	no effect of either drug on the pharmacokinetics or pharmacodynamics of the other 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	4047	4058	Active ingredient	carbamazepine 	consensus set annotator team		3953	3966	Positive	Qualitative	Elevated carbamazepine levels 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	3675	3686	Active ingredient	ethanol 	consensus set annotator team		3578	3585	Negative	Qualitative	no effect of either drug on the pharmacokinetics or pharmacodynamics of the other 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	4801	4812	Active ingredient	tacrine 	consensus set annotator team		4784	4791	Positive	Quantitative	five- and eight-fold increases in tacrine Cmax and AUC 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	6834	6845	Active ingredient	digoxin 	consensus set annotator team		6977	6984	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	5416	5427	Active ingredient	clomipramine 	consensus set annotator team		5455	5467	Positive	Qualitative	Significantly increased plasma TCA levels 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	7968	7979	Active ingredient	atenolol 	consensus set annotator team		8084	8092	Negative	Qualitative	did not affect the plasma concentrations 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	7199	7210	Active ingredient	propranolol 	consensus set annotator team		7351	7362	Positive	Quantitative	resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	5416	5427	Active ingredient	clomipramine 	consensus set annotator team		5455	5467	Positive	Qualitative	Significantly increased plasma TCA levels have been reported 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	5416	5427	Active ingredient	amitriptyline 	consensus set annotator team		5440	5453	Positive	Qualitative	Significantly increased plasma TCA levels have been reported 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	5416	5427	Active ingredient	imipramine 	consensus set annotator team		5471	5481	Positive	Qualitative	Significantly increased plasma TCA levels have been reported 	consensus set annotator team
9	Active ingredient	warfarin 	consensus set annotator team	2402	2410	Active ingredient	fluvoxamine 	consensus set annotator team		2303	2314	Positive	Qualitative	A clinically significant fluvoxamine interaction 	consensus set annotator team
9	Active ingredient	theophylline 	consensus set annotator team	2412	2424	Active ingredient	fluvoxamine 	consensus set annotator team		2303	2314	Positive	Qualitative	A clinically significant fluvoxamine interaction 	consensus set annotator team
9	Active ingredient	phenytoin 	consensus set annotator team	2466	2475	Active ingredient	fluvoxamine 	consensus set annotator team		2303	2314	Positive	Qualitative	A clinically significant fluvoxamine interaction 	consensus set annotator team
9	Active ingredient	omeprazole 	consensus set annotator team	2451	2461	Active ingredient	fluvoxamine 	consensus set annotator team		2303	2314	Positive	Qualitative	A clinically significant fluvoxamine interaction 	consensus set annotator team
9	Active ingredient	lorazepam 	consensus set annotator team	3197	3206	Active ingredient	fluvoxamine 	consensus set annotator team		3105	3116	Negative	Qualitative	no significant pharmacokinetic interaction 	consensus set annotator team
9	Active ingredient	fluvoxamine 	consensus set annotator team	3675	3686	Active ingredient	ethanol 	consensus set annotator team		3578	3585	Negative	Quantitative	revealed no effect of either drug on the pharmacokinetics 	consensus set annotator team
9	Active ingredient	pimozide 	consensus set annotator team	2392	2400	Active ingredient	fluvoxamine 	consensus set annotator team		2303	2314	Positive	Qualitative	A clinically significant fluvoxamine interaction 	consensus set annotator team
11	Active ingredient	cimetidine 	consensus set annotator team	83	93	Active ingredient	sertraline 	consensus set annotator team		161	171	Positive	Quantitative	increases in sertraline mean AUC (50%), C max (24%) and half-life (26 	consensus set annotator team
12	Active ingredient	sertraline 	consensus set annotator team	419	429	Metabolite	desmethyldiazepam 	consensus set annotator team	diazepam 	394	411	Positive	Quantitative	23% increase in T max 	consensus set annotator team
12	Active ingredient	sertraline 	consensus set annotator team	123	133	Active ingredient	diazepam 	consensus set annotator team		230	238	Positive	Quantitative	32% decrease relative to baseline in diazepam clearance 	consensus set annotator team
13	Active ingredient	sertraline 	consensus set annotator team	87	97	Active ingredient	lithium 	consensus set annotator team		139	146	Negative	Qualitative	did not significantly alter steady-state lithium levels or the renal clearance 	consensus set annotator team
14	Active ingredient	sertraline 	consensus set annotator team	66	76	Active ingredient	pimozide 	consensus set annotator team		49	57	Positive	Quantitative	increase in pimozide AUC and C max of about 40% 	consensus set annotator team
15	Active ingredient	sertraline 	consensus set annotator team	98	108	Active ingredient	phenytoin 	consensus set annotator team		172	181	Negative	Qualitative	does not produce clinically important inhibition of phenytoin metabolism 	consensus set annotator team
16	Active ingredient	sertraline 	consensus set annotator team	231	241	Active ingredient	cisapride 	consensus set annotator team		315	324	Negative	Qualitative	did not increase plasma concentrations 	consensus set annotator team
16	Active ingredient	sertraline 	consensus set annotator team	231	241	Active ingredient	terfenadine 	consensus set annotator team		284	295	Negative	Qualitative	did not increase plasma concentrations 	consensus set annotator team
16	Active ingredient	sertraline 	consensus set annotator team	231	241	Active ingredient	carbamazepine 	consensus set annotator team		297	310	Negative	Qualitative	did not increase plasma concentrations 	consensus set annotator team
16	Active ingredient	sertraline 	consensus set annotator team	514	524	Active ingredient	cisapride 	consensus set annotator team		490	499	Positive	Quantitative	induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35% 	consensus set annotator team
17	Active ingredient	sertraline 	consensus set annotator team	70	80	Active ingredient	tolbutamide 	consensus set annotator team		220	231	Positive	Quantitative	16% decrease from baseline in the clearance 	consensus set annotator team
19	Active ingredient	sertraline 	consensus set annotator team	70	80	Active ingredient	digoxin 	consensus set annotator team		158	165	Negative	Qualitative	did not change serum digoxin levels 	consensus set annotator team
21	Active ingredient	fluconazole 	consensus set annotator team	333	344	Active ingredient	norethindrone 	consensus set annotator team		511	524	Positive	Qualitative	resulted in small increases in the mean AUCs 	consensus set annotator team
21	Active ingredient	fluconazole 	consensus set annotator team	333	344	Active ingredient	ethinyl estradiol 	consensus set annotator team		489	506	Positive	Qualitative	resulted in small increases in the mean AUCs 	consensus set annotator team
22	Active ingredient	fluconazole 	consensus set annotator team	282	293	Active ingredient	ethinyl estradiol 	consensus set annotator team		316	333	Negative	Qualitative	no significant difference in ethinyl estradiol or levonorgestrel AUC 	consensus set annotator team
22	Active ingredient	fluconazole 	consensus set annotator team	282	293	Active ingredient	levonorgestrel 	consensus set annotator team		226	240	Negative	Qualitative	no significant difference in ethinyl estradiol or levonorgestrel AUC 	consensus set annotator team
23	Active ingredient	cimetidine 	consensus set annotator team	179	189	Active ingredient	fluconazole 	consensus set annotator team		287	298	Positive	Quantitative	decrease in fluconazole AUC of 13% ? 11% (range: -3.4 to -31%) and Cmax decreased 19% ? 14% (range: -5 to -40% 	consensus set annotator team
23	Active ingredient	cimetidine 	consensus set annotator team	419	429	Active ingredient	fluconazole 	consensus set annotator team		546	557	Negative	Qualitative	did not affect the bioavailability or pharmacokinetics 	consensus set annotator team
24	Active ingredient	rifampin 	consensus set annotator team	76	84	Active ingredient	Fluconazole 	consensus set annotator team		435	446	Positive	Quantitative	half-life decreased from 33.4 ? 4.4 hours to 26.8 ? 3.9 hours 	consensus set annotator team
24	Active ingredient	rifampin 	consensus set annotator team	76	84	Active ingredient	fluconazole 	consensus set annotator team		47	58	Positive	Qualitative	significant decrease in fluconazole AUC 	consensus set annotator team
25	Active ingredient	fluconazole 	consensus set annotator team	186	197	Active ingredient	phenytoin 	consensus set annotator team		349	358	Positive	Quantitative	increase in phenytoin AUC was 88% 	consensus set annotator team
26	Active ingredient	fluconazole 	consensus set annotator team	81	92	Active ingredient	cyclosporine 	consensus set annotator team		304	316	Positive	Qualitative	significant increase in cyclosporine AUC, Cmax, Cmin 	consensus set annotator team
27	Active ingredient	fluconazole 	consensus set annotator team	304	315	Active ingredient	zidovudine 	consensus set annotator team		257	267	Positive	Qualitative	significant increase in zidovudine AUC 	consensus set annotator team
28	Active ingredient	fluconazole 	consensus set annotator team	155	166	Active ingredient	theophylline 	consensus set annotator team		354	366	Positive	Qualitative	significant increases in theophylline AUC, Cmax, and half-life 	consensus set annotator team
28	Active ingredient	fluconazole 	consensus set annotator team	155	166	Active ingredient	theophylline 	consensus set annotator team		354	366	Positive	Qualitative	significant increases in theophylline AUC, Cmax, and half-life 	consensus set annotator team
29	Active ingredient	fluconazole 	consensus set annotator team	142	153	Active ingredient	Tolbutamide 	consensus set annotator team		237	248	Positive	Quantitative	Tolbutamide Cmax increased 11% 	consensus set annotator team
29	Active ingredient	fluconazole 	consensus set annotator team	142	153	Active ingredient	tolbutamide 	consensus set annotator team		189	200	Positive	Quantitative	increase in tolbutamide AUC of 26% 	consensus set annotator team
30	Active ingredient	fluconazole 	consensus set annotator team	112	123	Active ingredient	glipizide 	consensus set annotator team		20	29	Positive	Qualitative	The AUC and Cmax of glipizide (2.5 mg single dose) were significantly increased 	consensus set annotator team
31	Active ingredient	fluconazole 	consensus set annotator team	110	121	Active ingredient	glyburide 	consensus set annotator team		20	29	Positive	Qualitative	The AUC and Cmax of glyburide (5 mg single dose) were significantly increased 	consensus set annotator team
32	Active ingredient	fluconazole 	consensus set annotator team	636	647	Active ingredient	midazolam 	consensus set annotator team		662	671	Positive	Quantitative	increased the midazolam AUC and Cmax by 259% and 74% 	consensus set annotator team
32	Active ingredient	Fluconazole 	consensus set annotator team	441	452	Active ingredient	midazolam 	consensus set annotator team		481	490	Positive	Quantitative	reduced the clearance of IV midazolam by 51% 	consensus set annotator team
32	Active ingredient	fluconazole 	consensus set annotator team	527	538	Active ingredient	midazolam 	consensus set annotator team		553	562	Positive	Quantitative	increased the midazolam AUC and Cmax by 259% and 150% 	consensus set annotator team
33	Active ingredient	fluconazole 	consensus set annotator team	350	361	Active ingredient	azithromycin 	consensus set annotator team		366	378	Negative	Qualitative	no significant pharmacokinetic interaction 	consensus set annotator team
33	Active ingredient	azithromycin 	consensus set annotator team	366	378	Active ingredient	fluconazole 	consensus set annotator team		350	361	Negative	Qualitative	no significant pharmacokinetic interaction 	consensus set annotator team
35	Active ingredient	magnesium 	consensus set annotator team	20	29	Active ingredient	nitrofurantoin 	consensus set annotator team		80	94	Positive	Qualitative	reduce both the rate and extent of absorption 	consensus set annotator team
36	Active ingredient	probenecid 	consensus set annotator team	26	36	Active ingredient	nitrofurantoin 	consensus set annotator team		138	152	Positive	Qualitative	increase in nitrofurantoin serum levels 	consensus set annotator team
36	Active ingredient	sulfinpyrazone 	consensus set annotator team	41	55	Active ingredient	nitrofurantoin 	consensus set annotator team		138	152	Positive	Qualitative	increase in nitrofurantoin serum levels 	consensus set annotator team
38	Active ingredient	fluvoxamine 	consensus set annotator team	296	307	Active ingredient	thioridazine 	consensus set annotator team		172	184	Positive	Quantitative	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold 	consensus set annotator team
38	Active ingredient	fluvoxamine 	consensus set annotator team	296	307	Metabolite	mesoridazine 	consensus set annotator team	thioridazine 	217	229	Positive	Quantitative	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold 	consensus set annotator team
38	Active ingredient	fluvoxamine 	consensus set annotator team	296	307	Metabolite	sulforidazine 	consensus set annotator team	thioridazine 	234	247	Positive	Quantitative	Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold 	consensus set annotator team
40	Active ingredient	fluconazole 	consensus set annotator team	586	597	Active ingredient	glipizide 	consensus set annotator team		566	575	Positive	Quantitative	percentage increase in the glipizide AUC after fluconazole administration was 56.9% 	consensus set annotator team
42	Active ingredient	allopurinol 	consensus set annotator team	105	116	Active ingredient	mercaptopurine 	consensus set annotator team		241	255	Positive	Quantitative	a reduction in dose to approximately one-third to one-fourth of the usual dose 	consensus set annotator team
42	Active ingredient	allopurinol 	consensus set annotator team	105	116	Active ingredient	azathioprine 	consensus set annotator team		259	271	Positive	Quantitative	a reduction in dose to approximately one-third to one-fourth of the usual dose 	consensus set annotator team
44	Active ingredient	paroxetine 	consensus set annotator team	69	79	Active ingredient	pimozide 	consensus set annotator team		213	221	Positive	Quantitative	increases in pimozide AUC of 151% and Cmax of 62% 	consensus set annotator team
45	Active ingredient	phenobarbital 	consensus set annotator team	147	160	Active ingredient	paroxetine 	consensus set annotator team		115	125	Positive	Quantitative	AUC and T? were reduced (by an average of 25% and 38% 	consensus set annotator team
46	Active ingredient	paroxetine 	consensus set annotator team	365	375	Active ingredient	phenytoin 	consensus set annotator team		335	344	Positive	Quantitative	AUC was slightly reduced (12% on average) 	consensus set annotator team
46	Active ingredient	phenytoin 	consensus set annotator team	83	92	Active ingredient	paroxetine 	consensus set annotator team		51	61	Positive	Quantitative	AUC and T? were reduced (by an average of 50% and 35% 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	1273	1283	Active ingredient	atomoxetine 	consensus set annotator team		1464	1475	Positive	Quantitative	atomoxetine Cmax values that were 3- to 4-fold greater 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	752	762	Active ingredient	risperidone 	consensus set annotator team		1024	1035	Positive	Quantitative	increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	752	762	Metabolite	9-hydroxyrisperidone 	consensus set annotator team	risperidone 	907	927	Positive	Quantitative	decreased 9-hydroxyrisperidone concentrations approximately 10% 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	445	455	Active ingredient	desipramine 	consensus set annotator team		528	539	Positive	Quantitative	increased single-dose desipramine (100 mg) Cmax, AUC, and T? by an average of approximately 2-, 5-, and 3-fold 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	1273	1283	Active ingredient	atomoxetine 	consensus set annotator team		1403	1414	Positive	Quantitative	increases in steady state atomoxetine AUC values that were 6- to 8-fold greater 	consensus set annotator team
47	Active ingredient	paroxetine 	consensus set annotator team	752	762	Active ingredient	risperidone 	consensus set annotator team		863	874	Positive	Quantitative	increased mean plasma concentrations of risperidone approximately 4-fold 	consensus set annotator team
48	Active ingredient	paroxetine 	consensus set annotator team	93	103	Active ingredient	terfenadine 	consensus set annotator team		108	119	Negative	Qualitative	no effect of paroxetine on terfenadine pharmacokinetics 	consensus set annotator team
49	Active ingredient	paroxetine 	consensus set annotator team	133	143	Active ingredient	lithium 	consensus set annotator team		148	155	Negative	Qualitative	no pharmacokinetic interaction 	consensus set annotator team
49	Active ingredient	lithium 	consensus set annotator team	148	155	Active ingredient	paroxetine 	consensus set annotator team		133	143	Negative	Qualitative	no pharmacokinetic interaction 	consensus set annotator team
50	Active ingredient	paroxetine 	consensus set annotator team	39	49	Active ingredient	procyclidine 	consensus set annotator team		126	138	Positive	Quantitative	increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67% 	consensus set annotator team
51	Active ingredient	fosamprenavir/ritonavir 	consensus set annotator team	21	44	Active ingredient	paroxetine 	consensus set annotator team		50	60	Positive	Qualitative	significantly decreased plasma levels 	consensus set annotator team
53	Active ingredient	ketoconazole 	consensus set annotator team	93	105	Active ingredient	quinidine 	consensus set annotator team		66	75	Positive	Qualitative	quinidine levels rise when ketoconazole is coadministered 	consensus set annotator team
54	Active ingredient	quinidine 	consensus set annotator team	89	98	Active ingredient	diltiazem 	consensus set annotator team		130	139	Negative	Qualitative	does not alter the kinetics 	consensus set annotator team
54	Active ingredient	Diltiazem 	consensus set annotator team	0	9	Active ingredient	quinidine 	consensus set annotator team		74	83	Positive	Qualitative	decreases the clearance and increases the t1/2 of quinidine 	consensus set annotator team
56	Active ingredient	Zonisamide 	consensus set annotator team	0	10	Active ingredient	phenytoin 	consensus set annotator team		82	91	Negative	Qualitative	no appreciable effect on the steady-state plasma concentrations 	consensus set annotator team
56	Active ingredient	Zonisamide 	consensus set annotator team	0	10	Active ingredient	carbamazepine 	consensus set annotator team		93	106	Negative	Qualitative	no appreciable effect on the steady-state plasma concentrations 	consensus set annotator team
56	Active ingredient	Zonisamide 	consensus set annotator team	0	10	Active ingredient	valproate 	consensus set annotator team		111	120	Negative	Qualitative	no appreciable effect on the steady-state plasma concentrations 	consensus set annotator team
57	Active ingredient	cimetidine 	consensus set annotator team	71	81	Active ingredient	Zonisamide 	consensus set annotator team		0	10	Negative	Qualitative	pharmacokinetic parameters were not affected 	consensus set annotator team
59	Active ingredient	carbamazepine 	consensus set annotator team	20	33	Active ingredient	nefazodone 	consensus set annotator team		39	49	Positive	Qualitative	results in insufficient plasma concentrations 	consensus set annotator team
63	Active ingredient	phenytoin 	consensus set annotator team	465	474	Active ingredient	nisoldipine 	consensus set annotator team		564	575	Positive	Qualitative	lowered the nisoldipine plasma concentrations to undetectable levels 	consensus set annotator team
63	Active ingredient	Ranitidine 	consensus set annotator team	131	141	Active ingredient	nisoldipine 	consensus set annotator team		197	208	Negative	Quantitative	did not interact significantly with nisoldipine (AUC was decreased by 15-20%) 	consensus set annotator team
63	Active ingredient	cimetidine 	consensus set annotator team	100	110	Active ingredient	nisoldipine 	consensus set annotator team		40	51	Positive	Quantitative	A 30 to 45% increase in AUC and Cmax of nisoldipine was observed 	consensus set annotator team
63	Active ingredient	nisoldipine 	consensus set annotator team	1256	1267	Active ingredient	quinidine 	consensus set annotator team		1285	1294	Positive	Quantitative	increased plasma quinidine concentrations by about 20% 	consensus set annotator team
63	Active ingredient	Quinidine 	consensus set annotator team	1123	1132	Active ingredient	nisoldipine 	consensus set annotator team		1186	1197	Positive	Quantitative	decreased the bioavailability (AUC) of nisoldipine by 26%, but not the peak concentration 	consensus set annotator team
63	Active ingredient	phenytoin 	consensus set annotator team	465	474	Active ingredient	Nisoldipine 	consensus set annotator team		510	521	Positive	Qualitative	lowered the nisoldipine plasma concentrations to undetectable levels 	consensus set annotator team
63	Active ingredient	nisoldipine 	consensus set annotator team	787	798	Active ingredient	atenolol 	consensus set annotator team		818	826	Negative	Qualitative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant 	consensus set annotator team
63	Active ingredient	nisoldipine 	consensus set annotator team	787	798	Active ingredient	propranolol 	consensus set annotator team		828	839	Negative	Qualitative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant 	consensus set annotator team
63	Active ingredient	atenolol 	consensus set annotator team	818	826	Active ingredient	nisoldipine 	consensus set annotator team		787	798	Negative	Qualitative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant 	consensus set annotator team
63	Active ingredient	propranolol 	consensus set annotator team	828	839	Active ingredient	nisoldipine 	consensus set annotator team		787	798	Negative	Qualitative	Pharmacokinetic interactions between nisoldipine and beta-blockers (atenolol, propranolol) were variable and not significant 	consensus set annotator team
65	Active ingredient	nefazodone 	consensus set annotator team	69	79	Active ingredient	triazolam 	consensus set annotator team		110	119	Positive	Quantitative	half-life and AUC increased 4-fold and peak concentrations increased 1.7-fold 	consensus set annotator team
65	Active ingredient	triazolam 	consensus set annotator team	251	260	Active ingredient	Nefazodone 	consensus set annotator team		199	209	Negative	Qualitative	plasma concentrations were unaffected 	consensus set annotator team
66	Active ingredient	alprazolam 	consensus set annotator team	237	247	Active ingredient	Nefazodone 	consensus set annotator team		185	195	Negative	Qualitative	plasma concentrations were unaffected 	consensus set annotator team
66	Active ingredient	nefazodone 	consensus set annotator team	31	41	Active ingredient	alprazolam 	consensus set annotator team		5	15	Positive	Quantitative	peak concentrations, AUC and half-life values for alprazolam increased by approximately 2-fold 	consensus set annotator team
68	Active ingredient	cimetidine 	consensus set annotator team	326	336	Active ingredient	bisoprolol 	consensus set annotator team		64	74	Negative	Qualitative	no clinically relevant interactions 	consensus set annotator team
68	Active ingredient	rifampin 	consensus set annotator team	18	26	Active ingredient	bisoprolol 	consensus set annotator team		64	74	Positive	Qualitative	increases the metabolic clearance of bisoprolol fumarate shortening its elimination half-life 	consensus set annotator team
70	Active ingredient	aluminum 	consensus set annotator team	64	72	Active ingredient	sotalol 	consensus set annotator team		18	25	Positive	Quantitative	reduction in Cmax and AUC of 26% and 20% 	consensus set annotator team
70	Active ingredient	magnesium 	consensus set annotator team	83	92	Active ingredient	sotalol 	consensus set annotator team		18	25	Positive	Quantitative	reduction in Cmax and AUC of 26% and 20% 	consensus set annotator team
72	Active ingredient	rifampin 	consensus set annotator team	1800	1808	Active ingredient	oxycodone 	consensus set annotator team		1877	1886	Positive	Qualitative	decreased plasma oxycodone concentrations 	consensus set annotator team
72	Active ingredient	voriconazole 	consensus set annotator team	1123	1135	Active ingredient	oxycodone 	consensus set annotator team		1210	1219	Positive	Qualitative	increased the plasma concentrations 	consensus set annotator team
73	Active ingredient	rifampin 	consensus set annotator team	6968	6976	Active ingredient	oxycodone 	consensus set annotator team		7024	7033	Positive	Quantitative	decreased oxycodone AUC and Cmax values by 86% and 63% 	consensus set annotator team
73	Active ingredient	voriconazole 	consensus set annotator team	6794	6806	Active ingredient	oxycodone 	consensus set annotator team		6838	6847	Positive	Quantitative	increased oxycodone AUC and Cmax by 3.6 and 1.7 fold 	consensus set annotator team
74	Active ingredient	Omeprazole 	consensus set annotator team	536	546	Active ingredient	diazepam 	consensus set annotator team		578	586	Positive	Qualitative	prolong the elimination 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	189	199	Active ingredient	iron 	consensus set annotator team		353	357	Positive	Qualitative	interfere with absorption 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	189	199	Active ingredient	ampicillin 	consensus set annotator team		330	340	Positive	Qualitative	interfere with absorption 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	189	199	Active ingredient	ketoconazole 	consensus set annotator team		316	328	Positive	Qualitative	interfere with absorption 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	2122	2132	Active ingredient	atazanavir 	consensus set annotator team		2364	2374	Positive	Qualitative	substantially decrease atazanavir plasma concentrations 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	2966	2976	Metabolite	M8 	consensus set annotator team	nelfinavir 	3100	3102	Positive	Quantitative	AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	3626	3636	Active ingredient	saquinavir 	consensus set annotator team		3421	3431	Positive	Quantitative	increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	3943	3953	Active ingredient	tacrolimus 	consensus set annotator team		3958	3968	Positive	Qualitative	may increase the serum levels 	consensus set annotator team
74	Active ingredient	Omeprazole 	consensus set annotator team	536	546	Active ingredient	warfarin 	consensus set annotator team		588	596	Positive	Qualitative	prolong the elimination 	consensus set annotator team
74	Active ingredient	Omeprazole 	consensus set annotator team	536	546	Active ingredient	phenytoin 	consensus set annotator team		601	610	Positive	Qualitative	prolong the elimination 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	1408	1418	Active ingredient	theophylline 	consensus set annotator team		1083	1095	Negative	Qualitative	no interaction 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	1408	1418	Active ingredient	propranolol 	consensus set annotator team		1099	1110	Negative	Qualitative	no interaction 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	1408	1418	Active ingredient	cyclosporine 	consensus set annotator team		1237	1249	Positive	Qualitative	reports of interaction with other drugs metabolized via the cytochrome P450 system 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	1408	1418	Active ingredient	disulfiram 	consensus set annotator team		1251	1261	Positive	Qualitative	reports of interaction with other drugs metabolized via the cytochrome P450 system 	consensus set annotator team
74	Active ingredient	voriconazole 	consensus set annotator team	1809	1821	Active ingredient	omeprazole 	consensus set annotator team		1881	1891	Positive	Quantitative	increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	3626	3636	Active ingredient	saquinavir 	consensus set annotator team		3570	3580	Positive	Quantitative	elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	3626	3636	Active ingredient	ritonavir 	consensus set annotator team		3581	3590	Positive	Quantitative	elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	2966	2976	Active ingredient	nelfinavir 	consensus set annotator team		2936	2946	Positive	Quantitative	AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	2896	2906	Active ingredient	nelfinavir 	consensus set annotator team		2817	2827	Positive	Qualitative	decreased serum levels have been reported 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	3160	3170	Active ingredient	atazanavir 	consensus set annotator team		3132	3142	Positive	Quantitative	AUC was decreased by 94%, Cmax by 96%, and Cmin by 95% 	consensus set annotator team
74	Active ingredient	omeprazole 	consensus set annotator team	2896	2906	Active ingredient	atazanavir 	consensus set annotator team		2802	2812	Positive	Qualitative	decreased serum levels have been reported 	consensus set annotator team
74	Active ingredient	voriconazole 	consensus set annotator team	1495	1507	Active ingredient	omeprazole 	consensus set annotator team		1480	1490	Positive	Quantitative	in more than doubling of the omeprazole exposure 	consensus set annotator team
75	Active ingredient	omeprazole 	consensus set annotator team	8230	8240	Metabolite	14-hydroxy-clarithromycin 	consensus set annotator team	clarithromycin 	8152	8177	Positive	Qualitative	The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased 	consensus set annotator team
75	Active ingredient	omeprazole 	consensus set annotator team	8230	8240	Active ingredient	clarithromycin 	consensus set annotator team		8133	8147	Positive	Qualitative	The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased 	consensus set annotator team
75	Active ingredient	omeprazole 	consensus set annotator team	8402	8412	Metabolite	14-hydroxy-clarithromycin 	consensus set annotator team	clarithromycin 	8492	8517	Positive	Quantitative	mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater 	consensus set annotator team
75	Active ingredient	clarithromycin 	consensus set annotator team	7604	7618	Active ingredient	omeprazole 	consensus set annotator team		7714	7724	Positive	Quantitative	increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89% and 34 	consensus set annotator team
75	Active ingredient	omeprazole 	consensus set annotator team	8402	8412	Active ingredient	clarithromycin 	consensus set annotator team		8246	8260	Positive	Quantitative	mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater 	consensus set annotator team
76	Active ingredient	cimetidine 	consensus set annotator team	100	110	Active ingredient	citalopram 	consensus set annotator team		50	60	Positive	Quantitative	increase in citalopram AUC and Cmax of 43% and 39% 	consensus set annotator team
77	Active ingredient	citalopram 	consensus set annotator team	89	99	Active ingredient	digoxin 	consensus set annotator team		208	215	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
77	Active ingredient	digoxin 	consensus set annotator team	104	111	Active ingredient	citalopram 	consensus set annotator team		89	99	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
78	Active ingredient	Citalopram 	consensus set annotator team	229	239	Active ingredient	pimozide 	consensus set annotator team		278	286	Negative	Qualitative	did not alter the mean AUC or Cmax 	consensus set annotator team
79	Active ingredient	citalopram 	consensus set annotator team	28	38	Active ingredient	warfarin 	consensus set annotator team		90	98	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
80	Active ingredient	citalopram 	consensus set annotator team	27	37	Active ingredient	ketoconazole 	consensus set annotator team		50	62	Positive	Quantitative	decreased the Cmax and AUC of ketoconazole by 21% and 10% 	consensus set annotator team
80	Active ingredient	ketoconazole 	consensus set annotator team	50	62	Active ingredient	citalopram 	consensus set annotator team		27	37	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
81	Active ingredient	citalopram 	consensus set annotator team	28	38	Active ingredient	metoprolol 	consensus set annotator team		135	145	Positive	Quantitative	resulted in a two-fold increase in the plasma levels 	consensus set annotator team
83	Active ingredient	tacrine 	consensus set annotator team	20	27	Active ingredient	theophylline 	consensus set annotator team		33	45	Positive	Quantitative	increased theophylline elimination half-life and average plasma theophylline concentrations by approximately 2-fold 	consensus set annotator team
84	Active ingredient	Cimetidine 	consensus set annotator team	0	10	Active ingredient	tacrine 	consensus set annotator team		41	48	Positive	Quantitative	increased the Cmax and AUC of tacrine by approximately 54% and 64% 	consensus set annotator team
85	Active ingredient	fluvoxamine 	consensus set annotator team	83	94	Active ingredient	tacrine 	consensus set annotator team		66	73	Positive	Quantitative	five- and eight-fold increases in tacrine Cmax and AUC 	consensus set annotator team
88	Drug product	SEPTRA 	consensus set annotator team	56	62	Active ingredient	phenytoin 	consensus set annotator team		113	122	Positive	Quantitative	increased the phenytoin half-life by 39% and decreased the phenytoin metabolic clearance rate by 27% 	consensus set annotator team
88	Drug product	SEPTRA 	consensus set annotator team	0	6	Active ingredient	phenytoin 	consensus set annotator team		45	54	Positive	Qualitative	may inhibit the hepatic metabolism 	consensus set annotator team
90	Active ingredient	aluminum hydroxide 	consensus set annotator team	3803	3821	Active ingredient	atomoxetine 	consensus set annotator team		3852	3863	Negative	Qualitative	no effect on atomoxetine hydrochloride bioavailability 	consensus set annotator team
90	Active ingredient	magnesium hydroxide	consensus set annotator team	3783	3802	Active ingredient	atomoxetine 	consensus set annotator team		3852	3863	Negative	Qualitative	no effect on atomoxetine hydrochloride bioavailability 	consensus set annotator team
90	Active ingredient	atomoxetine 	consensus set annotator team	2788	2799	Active ingredient	desipramine 	consensus set annotator team		2970	2981	Negative	Qualitative	did not alter the pharmacokinetics 	consensus set annotator team
90	Active ingredient	omeprazole 	consensus set annotator team	3823	3833	Active ingredient	atomoxetine 	consensus set annotator team		3852	3863	Negative	Qualitative	no effect on atomoxetine hydrochloride bioavailability 	consensus set annotator team
90	Active ingredient	atomoxetine 	consensus set annotator team	2481	2492	Active ingredient	midazolam 	consensus set annotator team		2651	2660	Positive	Quantitative	15% increase in AUC 	consensus set annotator team
90	Active ingredient	paroxetine 	consensus set annotator team	925	935	Active ingredient	atomoxetine 	consensus set annotator team		962	973	Positive	Quantitative	the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater 	consensus set annotator team
90	Active ingredient	fluoxetine 	consensus set annotator team	939	949	Active ingredient	atomoxetine 	consensus set annotator team		962	973	Positive	Quantitative	the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater 	consensus set annotator team
90	Active ingredient	paroxetine 	consensus set annotator team	732	742	Active ingredient	atomoxetine 	consensus set annotator team		780	791	Positive	Qualitative	increase atomoxetine steady-state plasma concentrations 	consensus set annotator team
90	Active ingredient	fluoxetine 	consensus set annotator team	744	754	Active ingredient	atomoxetine 	consensus set annotator team		780	791	Positive	Qualitative	increase atomoxetine steady-state plasma concentrations 	consensus set annotator team
90	Active ingredient	quinidine 	consensus set annotator team	760	769	Active ingredient	atomoxetine 	consensus set annotator team		780	791	Positive	Qualitative	increase atomoxetine steady-state plasma concentrations 	consensus set annotator team
91	Active ingredient	quinidine 	consensus set annotator team	3845	3854	Active ingredient	atomoxetine 	consensus set annotator team		3750	3761	Positive	Qualitative	results in a substantial increase in atomoxetine plasma exposure 	consensus set annotator team
91	Active ingredient	quinidine 	consensus set annotator team	3845	3854	Active ingredient	atomoxetine 	consensus set annotator team		3893	3904	Positive	Qualitative	increase in atomoxetine plasma exposure 	consensus set annotator team
91	Active ingredient	paroxetine 	consensus set annotator team	3830	3840	Active ingredient	atomoxetine 	consensus set annotator team		3893	3904	Positive	Qualitative	increase in atomoxetine plasma exposure 	consensus set annotator team
91	Active ingredient	fluoxetine 	consensus set annotator team	3818	3828	Active ingredient	atomoxetine 	consensus set annotator team		3893	3904	Positive	Qualitative	increase in atomoxetine plasma exposure 	consensus set annotator team
91	Active ingredient	quinidine 	consensus set annotator team	1682	1691	Active ingredient	atomoxetine 	consensus set annotator team		1533	1544	Positive	Qualitative	cause similar increases in exposure 	consensus set annotator team
91	Active ingredient	paroxetine 	consensus set annotator team	1666	1676	Active ingredient	atomoxetine 	consensus set annotator team		1533	1544	Positive	Qualitative	cause similar increases in exposure 	consensus set annotator team
91	Active ingredient	fluoxetine 	consensus set annotator team	1654	1664	Active ingredient	atomoxetine 	consensus set annotator team		1533	1544	Positive	Qualitative	cause similar increases in exposure 	consensus set annotator team
92	Active ingredient	voriconazole 	consensus set annotator team	65	77	Active ingredient	sirolimus 	consensus set annotator team		161	170	Positive	Quantitative	increased the Cmax and AUC of sirolimus (2 mg single dose) an average of 7-fold (90% CI: 5.7, 7.5) and 11-fold 	consensus set annotator team
94	Active ingredient	erythromycin 	consensus set annotator team	327	339	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	itraconazole 	consensus set annotator team	251	263	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	ketoconazole 	consensus set annotator team	226	238	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	fluvoxamine 	consensus set annotator team	299	310	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	nefazodone 	consensus set annotator team	276	286	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	increasing alprazolam AUC, are as follows: ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	erythromycin 	consensus set annotator team	327	339	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	ketoconazole 	consensus set annotator team	226	238	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	fluvoxamine 	consensus set annotator team	299	310	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	nefazodone 	consensus set annotator team	276	286	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
94	Active ingredient	itraconazole 	consensus set annotator team	251	263	Active ingredient	alprazolam 	consensus set annotator team		194	204	Positive	Quantitative	ketoconazole, 3.98 fold; itraconazole, 2.70 fold; nefazodone, 1.98 fold; fluvoxamine, 1.96 fold; and erythromycin, 1.61 fold 	consensus set annotator team
95	Active ingredient	nefazodone 	consensus set annotator team	20	30	Active ingredient	alprazolam 	consensus set annotator team		41	51	Positive	Quantitative	increased alprazolam concentration two-fold 	consensus set annotator team
96	Active ingredient	fluvoxamine 	consensus set annotator team	20	31	Active ingredient	alprazolam 	consensus set annotator team		90	100	Positive	Quantitative	doubled the maximum plasma concentration of alprazolam, decreased clearance by 49%, increased half-life by 71 	consensus set annotator team
97	Active ingredient	cimetidine 	consensus set annotator team	20	30	Active ingredient	alprazolam 	consensus set annotator team		77	87	Positive	Quantitative	increased the maximum plasma concentration of alprazolam by 86%, decreased clearance by 42%, and increased half-life by 16% 	consensus set annotator team
98	Active ingredient	alprazolam 	consensus set annotator team	183	193	Active ingredient	imipramine 	consensus set annotator team		43	53	Positive	Quantitative	increased an average of 31% and 20% 	consensus set annotator team
98	Active ingredient	alprazolam 	consensus set annotator team	183	193	Metabolite	desipramine 	consensus set annotator team	imipramine 	58	69	Positive	Quantitative	increased an average of 31% and 20% 	consensus set annotator team
99	Active ingredient	propoxyphene 	consensus set annotator team	20	32	Active ingredient	alprazolam 	consensus set annotator team		79	89	Positive	Quantitative	decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58% 	consensus set annotator team
100	Active ingredient	Carbamazepine 	consensus set annotator team	45	58	Active ingredient	alprazolam 	consensus set annotator team		138	148	Positive	Qualitative	increase alprazolam metabolism 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	digoxin 	consensus set annotator team		824	831	Positive	Qualitative	Absorption of drugs from the stomach may be diminished 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	levodopa 	consensus set annotator team		962	970	Positive	Qualitative	the rate and/or extent of absorption of drugs from the small bowel may be increased 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	ethanol 	consensus set annotator team		972	979	Positive	Qualitative	the rate and/or extent of absorption of drugs from the small bowel may be increased 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	cyclosporine 	consensus set annotator team		981	993	Positive	Qualitative	the rate and/or extent of absorption of drugs from the small bowel may be increased 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	tetracycline 	consensus set annotator team		948	960	Positive	Qualitative	the rate and/or extent of absorption of drugs from the small bowel may be increased 	consensus set annotator team
102	Active ingredient	metoclopramide 	consensus set annotator team	802	816	Active ingredient	acetaminophen 	consensus set annotator team		933	946	Positive	Qualitative	the rate and/or extent of absorption of drugs from the small bowel may be increased 	consensus set annotator team
104	Active ingredient	conivaptan 	consensus set annotator team	877	887	Active ingredient	amlodipine 	consensus set annotator team		978	988	Positive	Quantitative	a 2-fold increase in the AUC and half-life 	consensus set annotator team
104	Active ingredient	conivaptan 	consensus set annotator team	1125	1135	Active ingredient	digoxin 	consensus set annotator team		1078	1085	Positive	Quantitative	a 30% reduction in clearance and 79% and 43% increases in digoxin Cmax and AUC 	consensus set annotator team
104	Drug product	VAPRISOL 	consensus set annotator team	1333	1341	Active ingredient	warfarin 	consensus set annotator team		1406	1414	Positive	Quantitative	increased the mean S-warfarin AUC and S-warfarin Cmax by 14% and 17%, respectively 	consensus set annotator team
104	Active ingredient	furosemide 	consensus set annotator team	1821	1831	Active ingredient	conivaptan 	consensus set annotator team		1727	1737	Negative	Qualitative	The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged 	consensus set annotator team
104	Drug product	VAPRISOL 	consensus set annotator team	796	804	Active ingredient	simvastatin 	consensus set annotator team		859	870	Positive	Quantitative	resulted in a 3-fold increase in the AUC of simvastatin 	consensus set annotator team
104	Active ingredient	ketoconazole 	consensus set annotator team	267	279	Active ingredient	conivaptan 	consensus set annotator team		231	241	Positive	Quantitative	resulted in 4- and 11-fold increases in Cmax and AUC 	consensus set annotator team
104	Drug product	VAPRISOL 	consensus set annotator team	648	656	Active ingredient	midazolam 	consensus set annotator team		771	780	Positive	Quantitative	increased the mean AUC values by approximately 2- and 3-fold 	consensus set annotator team
104	Active ingredient	captopril 	consensus set annotator team	1802	1811	Active ingredient	conivaptan 	consensus set annotator team		1727	1737	Negative	Qualitative	The pharmacokinetics of oral conivaptan (20 - 40 mg/day) were unchanged 	consensus set annotator team
106	Active ingredient	propafenone 	consensus set annotator team	483	494	Active ingredient	metoprolol 	consensus set annotator team		518	528	Positive	Qualitative	are likely to increase 	consensus set annotator team
106	Active ingredient	fluoxetine 	consensus set annotator team	455	465	Active ingredient	metoprolol 	consensus set annotator team		518	528	Positive	Qualitative	are likely to increase 	consensus set annotator team
106	Active ingredient	quinidine 	consensus set annotator team	629	638	Active ingredient	metoprolol 	consensus set annotator team		668	678	Positive	Quantitative	tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life 	consensus set annotator team
106	Active ingredient	propafenone 	consensus set annotator team	844	855	Active ingredient	metoprolol 	consensus set annotator team		893	903	Positive	Quantitative	resulted in two- to five-fold increases in the steady-state concentration of metoprolol 	consensus set annotator team
106	Active ingredient	paroxetine 	consensus set annotator team	467	477	Active ingredient	metoprolol 	consensus set annotator team		518	528	Positive	Qualitative	are likely to increase 	consensus set annotator team
106	Active ingredient	quinidine 	consensus set annotator team	444	453	Active ingredient	metoprolol 	consensus set annotator team		518	528	Positive	Qualitative	are likely to increase 	consensus set annotator team
108	Active ingredient	nifedipine 	consensus set annotator team	476	486	Active ingredient	quinidine 	consensus set annotator team		419	428	Negative	Qualitative	exposure to quinidine was not importantly changed 	consensus set annotator team
108	Active ingredient	quinidine 	consensus set annotator team	130	139	Active ingredient	nifedipine 	consensus set annotator team		168	178	Positive	Quantitative	increased Cmax and AUC of nifedipine in healthy volunteers by factors of 2.30 and 1.37 	consensus set annotator team
109	Active ingredient	diltiazem 	consensus set annotator team	74	83	Active ingredient	nifedipine 	consensus set annotator team		235	245	Positive	Quantitative	Cmax values of nifedipine increased by factors of 2.0 and 1.7 	consensus set annotator team
110	Active ingredient	nifedipine 	consensus set annotator team	166	176	Active ingredient	irbesartan 	consensus set annotator team		194	204	Negative	Qualitative	had no effect on irbesartan pharmacokinetics 	consensus set annotator team
111	Active ingredient	nifedipine 	consensus set annotator team	202	212	Active ingredient	doxazosin 	consensus set annotator team		255	264	Positive	Quantitative	resulted in a decrease in AUC and Cmax of doxazosin to 83% and 86% 	consensus set annotator team
111	Active ingredient	doxazosin 	consensus set annotator team	357	366	Active ingredient	nifedipine 	consensus set annotator team		384	394	Positive	Quantitative	AUC and Cmax of nifedipine were increased by factors of 1.13 and 1.23 	consensus set annotator team
113	Active ingredient	cimetidine 	consensus set annotator team	624	634	Active ingredient	nifedipine 	consensus set annotator team		594	604	Positive	Quantitative	Cmax values of nifedipine in the presence of cimetidine were increased by factors ranging between 1.60 and 2.02 	consensus set annotator team
113	Active ingredient	cimetidine 	consensus set annotator team	417	427	Active ingredient	nifedipine 	consensus set annotator team		465	475	Positive	Quantitative	AUC values of nifedipine in the presence of cimetidine were between 1.52 and 2.01 times those in the absence 	consensus set annotator team
114	Active ingredient	dalfopristin 	consensus set annotator team	211	223	Active ingredient	nifedipine 	consensus set annotator team		228	238	Positive	Quantitative	increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18 	consensus set annotator team
114	Active ingredient	quinupristin 	consensus set annotator team	198	210	Active ingredient	nifedipine 	consensus set annotator team		228	238	Positive	Quantitative	increased AUC and Cmax for nifedipine by factors of 1.44 and 1.18 	consensus set annotator team
115	Active ingredient	phenytoin 	consensus set annotator team	136	145	Active ingredient	nifedipine 	consensus set annotator team		68	78	Positive	Quantitative	lowered the AUC and Cmax of nifedipine by approximately 70% 	consensus set annotator team
116	Active ingredient	rosiglitazone 	consensus set annotator team	36	49	Active ingredient	nifedipine 	consensus set annotator team		139	149	Negative	Qualitative	shown to have no clinically relevant effect on the pharmacokinetics 	consensus set annotator team
118	Drug product	Synercid 	consensus set annotator team	30	38	Active ingredient	nifedipine 	consensus set annotator team		282	292	Positive	Quantitative	Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33 	consensus set annotator team
118	Drug product	Synercid 	consensus set annotator team	30	38	Active ingredient	midazolam 	consensus set annotator team		297	306	Positive	Quantitative	Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33 	consensus set annotator team
122	Active ingredient	rifampin 	consensus set annotator team	170	178	Active ingredient	rosiglitazone 	consensus set annotator team		204	217	Positive	Qualitative	may decrease the AUC 	consensus set annotator team
122	Active ingredient	gemfibrozil 	consensus set annotator team	87	98	Active ingredient	rosiglitazone 	consensus set annotator team		124	137	Positive	Qualitative	may increase the AUC 	consensus set annotator team
123	Active ingredient	ranitidine 	consensus set annotator team	11699	11709	Active ingredient	rosiglitazone 	consensus set annotator team		11823	11836	Negative	Qualitative	did not alter the pharmacokinetics 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	10706	10713	Active ingredient	glimepiride 	consensus set annotator team		10645	10656	Negative	Quantitative	No clinically significant reductions in glimepiride AUC and Cmax were observed 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	9050	9057	Active ingredient	nifedipine 	consensus set annotator team		9152	9162	Negative	Qualitative	was shown to have no clinically relevant effect 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	9050	9057	Active ingredient	norethindrone 	consensus set annotator team		9210	9223	Negative	Qualitative	was shown to have no clinically relevant effect 	consensus set annotator team
123	Active ingredient	gemfibrozil 	consensus set annotator team	9317	9328	Active ingredient	rosiglitazone 	consensus set annotator team		9379	9392	Positive	Quantitative	increased rosiglitazone AUC by 127% 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	9050	9057	Active ingredient	nifedipine 	consensus set annotator team		9152	9162	Negative	Qualitative	no clinically relevant effect on the pharmacokinetics 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	9050	9057	Active ingredient	ethinyl estradiol 	consensus set annotator team		9188	9205	Negative	Qualitative	no clinically relevant effect on the pharmacokinetics 	consensus set annotator team
123	Active ingredient	metformin 	consensus set annotator team	10842	10851	Drug product	AVANDIA 	consensus set annotator team		10811	10818	Negative	Qualitative	had no effect on the steady-state pharmacokinetics 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	10811	10818	Active ingredient	metformin 	consensus set annotator team		10842	10851	Negative	Qualitative	had no effect on the steady-state pharmacokinetics 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	11391	11398	Active ingredient	warfarin 	consensus set annotator team		11473	11481	Negative	Qualitative	had no clinically relevant effect on the steady-state pharmacokinetics 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	11219	11226	Active ingredient	digoxin 	consensus set annotator team		11308	11315	Negative	Qualitative	did not alter the steady-state pharmacokinetics 	consensus set annotator team
123	Active ingredient	acarbose 	consensus set annotator team	11026	11034	Drug product	AVANDIA 	consensus set annotator team		11178	11185	Negative	Qualitative	had no clinically relevant effect on the pharmacokinetics 	consensus set annotator team
123	Active ingredient	glimepiride 	consensus set annotator team	10478	10489	Drug product	AVANDIA 	consensus set annotator team		10596	10603	Negative	Qualitative	had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	10434	10441	Active ingredient	glyburide 	consensus set annotator team		10362	10371	Positive	Qualitative	AUC and Cmax slightly increased 	consensus set annotator team
123	Drug product	AVANDIA 	consensus set annotator team	10201	10208	Active ingredient	glyburide 	consensus set annotator team		10295	10304	Positive	Quantitative	decrease in glyburide AUC and Cmax of approximately 30% 	consensus set annotator team
123	Active ingredient	Rifampin 	consensus set annotator team	9731	9739	Active ingredient	rosiglitazone 	consensus set annotator team		9833	9846	Positive	Quantitative	decrease rosiglitazone AUC by 66% 	consensus set annotator team
124	Active ingredient	propranolol 	consensus set annotator team	78	89	Active ingredient	propafenone 	consensus set annotator team		11	22	Positive	Quantitative	The AUC of propafenone is increased by more than 200% 	consensus set annotator team
125	Active ingredient	quinidine 	consensus set annotator team	65	74	Active ingredient	propranolol 	consensus set annotator team		18	29	Positive	Qualitative	metabolism of propranolol is reduced 	consensus set annotator team
126	Active ingredient	propranolol 	consensus set annotator team	104	115	Active ingredient	nifedipine 	consensus set annotator team		25	35	Positive	Quantitative	Cmax and AUC of nifedipine are increased by 64% and 79% 	consensus set annotator team
127	Active ingredient	Verapamil 	consensus set annotator team	80	89	Active ingredient	propranolol 	consensus set annotator team		130	141	Negative	Qualitative	does not affect the pharmacokinetics 	consensus set annotator team
127	Active ingredient	Propranolol 	consensus set annotator team	0	11	Active ingredient	verapamil 	consensus set annotator team		52	61	Negative	Qualitative	does not affect the pharmacokinetics 	consensus set annotator team
127	Active ingredient	Propranolol 	consensus set annotator team	0	11	Metabolite	norverapamil 	consensus set annotator team	verapamil 	66	78	Negative	Qualitative	does not affect the pharmacokinetics 	consensus set annotator team
128	Active ingredient	Diazepam 	consensus set annotator team	123	131	Active ingredient	propranolol 	consensus set annotator team		171	182	Negative	Qualitative	does not alter the pharmacokinetics 	consensus set annotator team
128	Active ingredient	Propranolol 	consensus set annotator team	0	11	Active ingredient	diazepam 	consensus set annotator team		42	50	Positive	Qualitative	can inhibit the metabolism 	consensus set annotator team
129	Active ingredient	aluminum hydroxide 	consensus set annotator team	171	189	Active ingredient	propranolol 	consensus set annotator team		232	243	Positive	Qualitative	decrease in propranolol concentrations 	consensus set annotator team
129	Active ingredient	cimetidine 	consensus set annotator team	38	48	Active ingredient	propranolol 	consensus set annotator team		21	32	Positive	Quantitative	increased propranolol AUC and Cmax by 46% and 35% 	consensus set annotator team
130	Active ingredient	metoclopramide 	consensus set annotator team	21	35	Active ingredient	propranolol 	consensus set annotator team		57	68	Negative	Qualitative	did not have a significant effect on propranolol�s pharmacokinetics 	consensus set annotator team
131	Active ingredient	colestipol 	consensus set annotator team	39	49	Active ingredient	propranolol 	consensus set annotator team		55	66	Positive	Quantitative	50% decrease in propranolol concentrations 	consensus set annotator team
131	Active ingredient	cholestyramine 	consensus set annotator team	21	35	Active ingredient	propranolol 	consensus set annotator team		55	66	Positive	Quantitative	50% decrease in propranolol concentrations 	consensus set annotator team
132	Active ingredient	propranolol 	consensus set annotator team	21	32	Active ingredient	lovastatin 	consensus set annotator team		38	48	Positive	Quantitative	decreased 18% to 23% the AUC 	consensus set annotator team
132	Active ingredient	propranolol 	consensus set annotator team	21	32	Active ingredient	pravastatin 	consensus set annotator team		52	63	Positive	Quantitative	decreased 18% to 23% the AUC 	consensus set annotator team
132	Active ingredient	Propranolol 	consensus set annotator team	145	156	Active ingredient	fluvastatin 	consensus set annotator team		207	218	Negative	Qualitative	not have an effect on the pharmacokinetics 	consensus set annotator team
133	Active ingredient	propranolol 	consensus set annotator team	33	44	Active ingredient	thioridazine 	consensus set annotator team		112	124	Positive	Quantitative	increased thioridazine plasma concentrations ranging from 55% to 369% 	consensus set annotator team
133	Active ingredient	propranolol 	consensus set annotator team	33	44	Metabolite	mesoridazine 	consensus set annotator team	thioridazine 	211	223	Positive	Quantitative	increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209% 	consensus set annotator team
134	Active ingredient	chlorpromazine 	consensus set annotator team	21	35	Active ingredient	propranolol 	consensus set annotator team		41	52	Positive	Quantitative	resulted in a 70% increase in propranolol plasma level 	consensus set annotator team
136	Active ingredient	ritonavir 	consensus set annotator team	263	272	Active ingredient	trazodone 	consensus set annotator team		347	356	Positive	Quantitative	Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52% 	consensus set annotator team
136	Active ingredient	indinavir 	consensus set annotator team	209	218	Active ingredient	trazodone 	consensus set annotator team		117	126	Positive	Qualitative	can be inhibited 	consensus set annotator team
136	Active ingredient	ritonavir 	consensus set annotator team	194	203	Active ingredient	trazodone 	consensus set annotator team		117	126	Positive	Qualitative	can be inhibited 	consensus set annotator team
137	Active ingredient	carbamazepine 	consensus set annotator team	124	137	Active ingredient	trazodone 	consensus set annotator team		171	180	Positive	Quantitative	reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively 	consensus set annotator team
137	Active ingredient	carbamazepine 	consensus set annotator team	124	137	Metabolite	mCPP 	consensus set annotator team	trazodone 	193	197	Positive	Quantitative	reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively 	consensus set annotator team
139	Active ingredient	ketoconazole 	consensus set annotator team	1638	1650	Active ingredient	fexofenadine 	consensus set annotator team		1693	1705	Positive	Qualitative	enhances fexofenadine gastrointestinal absorption 	consensus set annotator team
139	Active ingredient	erythromycin 	consensus set annotator team	1654	1666	Active ingredient	fexofenadine 	consensus set annotator team		1693	1705	Positive	Qualitative	enhances fexofenadine gastrointestinal absorption 	consensus set annotator team
139	Active ingredient	ketoconazole 	consensus set annotator team	619	631	Active ingredient	fexofenadine 	consensus set annotator team		690	702	Positive	Qualitative	increased plasma concentrations 	consensus set annotator team
139	Active ingredient	erythromycin 	consensus set annotator team	635	647	Active ingredient	fexofenadine 	consensus set annotator team		690	702	Positive	Qualitative	increased plasma concentrations 	consensus set annotator team
139	Active ingredient	Fexofenadine 	consensus set annotator team	730	742	Active ingredient	erythromycin 	consensus set annotator team		791	803	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
139	Active ingredient	erythromycin 	consensus set annotator team	635	647	Active ingredient	fexofenadine 	consensus set annotator team		580	592	Positive	Qualitative	increased plasma concentrations 	consensus set annotator team
139	Active ingredient	aluminum 	consensus set annotator team	273	281	Active ingredient	fexofenadine 	consensus set annotator team		202	214	Positive	Quantitative	decreased fexofenadine AUC by 41% and Cmax by 43% 	consensus set annotator team
139	Active ingredient	Fexofenadine 	consensus set annotator team	730	742	Active ingredient	ketoconazole 	consensus set annotator team		807	819	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
139	Active ingredient	magnesium 	consensus set annotator team	286	295	Active ingredient	fexofenadine 	consensus set annotator team		202	214	Positive	Quantitative	decreased fexofenadine AUC by 41% and Cmax by 43% 	consensus set annotator team
141	Active ingredient	cimetidine 	consensus set annotator team	251	261	Active ingredient	amlodipine 	consensus set annotator team		226	236	Negative	Qualitative	did not alter the pharmacokinetics 	consensus set annotator team
141	Active ingredient	amlodipine 	consensus set annotator team	1473	1483	Active ingredient	ethanol 	consensus set annotator team		1546	1553	Negative	Qualitative	no significant effect 	consensus set annotator team
141	Active ingredient	amlodipine 	consensus set annotator team	1590	1600	Active ingredient	warfarin 	consensus set annotator team		1615	1623	Negative	Qualitative	did not change 	consensus set annotator team
141	Active ingredient	aluminum 	consensus set annotator team	608	616	Active ingredient	amlodipine 	consensus set annotator team		657	667	Negative	Qualitative	had no significant effect on the pharmacokinetics 	consensus set annotator team
141	Active ingredient	magnesium 	consensus set annotator team	594	603	Active ingredient	amlodipine 	consensus set annotator team		657	667	Negative	Qualitative	had no significant effect on the pharmacokinetics 	consensus set annotator team
141	Active ingredient	amlodipine 	consensus set annotator team	1296	1306	Active ingredient	digoxin 	consensus set annotator team		1321	1328	Negative	Qualitative	did not change 	consensus set annotator team
141	Active ingredient	sildenafil 	consensus set annotator team	792	802	Active ingredient	amlodipine 	consensus set annotator team		894	904	Negative	Qualitative	had no effect on the pharmacokinetic parameters 	consensus set annotator team
141	Active ingredient	amlodipine 	consensus set annotator team	1117	1127	Active ingredient	atorvastatin 	consensus set annotator team		1151	1163	Negative	Qualitative	no significant change in the steady-state pharmacokinetic parameters 	consensus set annotator team
145	Active ingredient	valproate 	consensus set annotator team	73	82	Drug product	Felbatol 	consensus set annotator team		103	111	Negative	Qualitative	no significant effect of valproate on the clearance 	consensus set annotator team
145	Active ingredient	valproate 	consensus set annotator team	157	166	Active ingredient	felbamate 	consensus set annotator team		236	245	Positive	Qualitative	not expected to cause a clinically important effect on Felbatolﾫ (felbamate) plasma concentrations 	consensus set annotator team
146	Active ingredient	Felbamate 	consensus set annotator team	370	379	Active ingredient	gestodene 	consensus set annotator team		424	433	Positive	Quantitative	42% decrease in the gestodene AUC 0-24 	consensus set annotator team
146	Active ingredient	Felbamate 	consensus set annotator team	370	379	Active ingredient	estradiol 	consensus set annotator team		536	545	Negative	Qualitative	no clinically relevant effect was observed on the pharmacokinetic parameters 	consensus set annotator team
147	Drug product	Felbatol 	consensus set annotator team	11	19	Active ingredient	phenytoin 	consensus set annotator team		56	65	Positive	Quantitative	increased the steady-state phenytoin Cmin to 25?7 micrograms/mL 	consensus set annotator team
147	Active ingredient	felbamate 	consensus set annotator team	362	371	Active ingredient	phenytoin 	consensus set annotator team		444	453	Positive	Quantitative	increased the steady-state phenytoin Cmin to 25?7 micrograms/mL 	consensus set annotator team
148	Drug product	Felbatol 	consensus set annotator team	15	23	Active ingredient	carbamazepine 	consensus set annotator team		63	76	Positive	Qualitative	decrease in the steady-state carbamazepine plasma concentrations 	consensus set annotator team
148	Drug product	Felbatol 	consensus set annotator team	15	23	Metabolite	carbamazepine epoxide 	consensus set annotator team	carbamazepine 	135	156	Positive	Qualitative	increase in the steady-state carbamazepine epoxide plasma concentration 	consensus set annotator team
148	Active ingredient	felbamate 	consensus set annotator team	609	618	Metabolite	Carbamazepine epoxide 	consensus set annotator team	carbamazepine 	481	502	Positive	Quantitative	Cmin concentrations increased 57 	consensus set annotator team
148	Active ingredient	felbamate 	consensus set annotator team	411	420	Active ingredient	carbamazepine 	consensus set annotator team		339	352	Positive	Quantitative	Cmin decreased 31% 	consensus set annotator team
149	Drug product	Felbatol 	consensus set annotator team	11	19	Active ingredient	valproate 	consensus set annotator team		56	65	Positive	Qualitative	increase in steady-state valproate concentrations 	consensus set annotator team
149	Drug product	Felbatol 	consensus set annotator team	881	889	Active ingredient	valproate 	consensus set annotator team		819	828	Negative	Qualitative	protein binding of valproate did not change 	consensus set annotator team
149	Active ingredient	felbamate 	consensus set annotator team	341	350	Active ingredient	valproate 	consensus set annotator team		398	407	Positive	Quantitative	increased the steady-state valproate Cmin to 96?25 micrograms/mL 	consensus set annotator team
150	Active ingredient	felbamate 	consensus set annotator team	35	44	Active ingredient	phenobarbital 	consensus set annotator team		50	63	Negative	Qualitative	increase in phenobarbital plasma concentrations 	consensus set annotator team
150	Active ingredient	felbamate 	consensus set annotator team	359	368	Active ingredient	phenobarbital 	consensus set annotator team		219	232	Positive	Quantitative	Cmin concentration increased to 17.8 micrograms/mL 	consensus set annotator team
151	Active ingredient	phenytoin 	consensus set annotator team	142	151	Drug product	Felbatol 	consensus set annotator team		232	240	Positive	Quantitative	45% decrease in the steady-state trough concentrations 	consensus set annotator team
151	Active ingredient	Phenytoin 	consensus set annotator team	11	20	Active ingredient	felbamate 	consensus set annotator team		83	92	Positive	Quantitative	causes an approximate doubling of the clearance 	consensus set annotator team
152	Active ingredient	carbamazepine 	consensus set annotator team	142	155	Drug product	Felbatol 	consensus set annotator team		240	248	Positive	Quantitative	40% decrease in the steady-state trough concentrations 	consensus set annotator team
152	Active ingredient	Carbamazepine 	consensus set annotator team	15	28	Drug product	Felbatol 	consensus set annotator team		84	92	Positive	Quantitative	causes an approximate 50% increase in the clearance 	consensus set annotator team
155	Active ingredient	ritonavir 	consensus set annotator team	8627	8636	Active ingredient	sildenafil 	consensus set annotator team		8770	8780	Positive	Quantitative	resulted in a 300% (4-fold) increase in sildenafil Cmax 	consensus set annotator team
155	Active ingredient	Sildenafil 	consensus set annotator team	12437	12447	Active ingredient	levonorgestrel 	consensus set annotator team		12536	12550	Negative	Qualitative	had no impact on the plasma levels 	consensus set annotator team
155	Active ingredient	Sildenafil 	consensus set annotator team	12437	12447	Active ingredient	ethinyl estradiol 	consensus set annotator team		12507	12524	Negative	Qualitative	had no impact on the plasma levels 	consensus set annotator team
155	Active ingredient	magnesium hydroxide 	consensus set annotator team	12777	12796	Active ingredient	sildenafil 	consensus set annotator team		12855	12865	Negative	Qualitative	did not affect the bioavailability 	consensus set annotator team
155	Active ingredient	levonorgestrel 	consensus set annotator team	12362	12376	Active ingredient	sildenafil 	consensus set annotator team		12425	12435	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
155	Active ingredient	sildenafil 	consensus set annotator team	11970	11980	Active ingredient	ritonavir 	consensus set annotator team		12085	12094	Negative	Qualitative	did not affect the steady-state pharmacokinetics 	consensus set annotator team
155	Active ingredient	sildenafil 	consensus set annotator team	11970	11980	Active ingredient	saquinavir 	consensus set annotator team		12070	12080	Negative	Qualitative	did not affect the steady-state pharmacokinetics 	consensus set annotator team
155	Active ingredient	aluminum hydroxide 	consensus set annotator team	12797	12815	Active ingredient	sildenafil 	consensus set annotator team		12855	12865	Negative	Qualitative	did not affect the bioavailability 	consensus set annotator team
155	Active ingredient	sildenafil 	consensus set annotator team	12630	12640	Active ingredient	atorvastatin 	consensus set annotator team		12727	12739	Negative	Qualitative	did not alter the pharmacokinetics of either sildenafil 	consensus set annotator team
155	Active ingredient	atorvastatin 	consensus set annotator team	12655	12667	Active ingredient	sildenafil 	consensus set annotator team		12713	12723	Negative	Qualitative	did not alter the pharmacokinetics of either sildenafil 	consensus set annotator team
155	Active ingredient	ethinyl estradiol 	consensus set annotator team	12333	12350	Active ingredient	sildenafil 	consensus set annotator team		12425	12435	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
155	Active ingredient	sildenafil 	consensus set annotator team	10714	10724	Active ingredient	bosentan 	consensus set annotator team		11010	11018	Positive	Quantitative	50% increase in AUC of bosentan 	consensus set annotator team
155	Active ingredient	bosentan 	consensus set annotator team	10758	10766	Active ingredient	sildenafil 	consensus set annotator team		10938	10948	Positive	Quantitative	55% decrease in sildenafil Cmax 	consensus set annotator team
155	Active ingredient	bosentan 	consensus set annotator team	10758	10766	Active ingredient	sildenafil 	consensus set annotator team		10901	10911	Positive	Quantitative	63% decrease of sildenafil AUC 	consensus set annotator team
155	Active ingredient	epoprostenol 	consensus set annotator team	11364	11376	Active ingredient	sildenafil 	consensus set annotator team		11297	11307	Positive	Quantitative	22% lower mean average steady state concentrations 	consensus set annotator team
155	Active ingredient	saquinavir 	consensus set annotator team	10265	10275	Active ingredient	sildenafil 	consensus set annotator team		10394	10404	Positive	Quantitative	resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC 	consensus set annotator team
155	Active ingredient	saquinavir 	consensus set annotator team	10265	10275	Active ingredient	sildenafil 	consensus set annotator team		10433	10443	Positive	Quantitative	210% increase in sildenafil AUC 	consensus set annotator team
155	Active ingredient	ritonavir 	consensus set annotator team	8627	8636	Active ingredient	sildenafil 	consensus set annotator team		8820	8830	Positive	Quantitative	1000% (11-fold) increase in sildenafil plasma AUC 	consensus set annotator team
155	Active ingredient	saquinavir 	consensus set annotator team	9146	9156	Active ingredient	sildenafil 	consensus set annotator team		9238	9248	Positive	Qualitative	expected to increase sildenafil levels 	consensus set annotator team
155	Active ingredient	erythromycin 	consensus set annotator team	10033	10045	Active ingredient	sildenafil 	consensus set annotator team		10136	10146	Positive	Quantitative	182% increase in sildenafil systemic exposure (AUC 	consensus set annotator team
155	Active ingredient	Cimetidine 	consensus set annotator team	9791	9801	Active ingredient	sildenafil 	consensus set annotator team		9873	9883	Positive	Quantitative	caused a 56% increase in plasma sildenafil concentrations 	consensus set annotator team
156	Active ingredient	irbesartan 	consensus set annotator team	160	170	Active ingredient	aliskiren 	consensus set annotator team		179	188	Positive	Quantitative	reduced aliskiren Cmax up to 50 	consensus set annotator team
156	Active ingredient	itraconazole 	consensus set annotator team	940	952	Active ingredient	aliskiren 	consensus set annotator team		965	974	Positive	Quantitative	resulted in approximately 5.8-fold increase in Cmax and 6.5-fold increase in AUC 	consensus set annotator team
156	Active ingredient	furosemide 	consensus set annotator team	1680	1690	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	atenolol 	consensus set annotator team	1660	1668	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	warfarin 	consensus set annotator team	1670	1678	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	celecoxib 	consensus set annotator team	1701	1710	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	digoxin 	consensus set annotator team	1692	1699	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	ramipril 	consensus set annotator team	1733	1741	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	valsartan 	consensus set annotator team	1743	1752	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	hydrochlorothiazide 	consensus set annotator team	1712	1731	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	amlodipine 	consensus set annotator team	1768	1778	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	metformin 	consensus set annotator team	1754	1763	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	ketoconazole 	consensus set annotator team	692	704	Active ingredient	aliskiren 	consensus set annotator team		710	719	Positive	Quantitative	80% increase in plasma levels of aliskiren 	consensus set annotator team
156	Active ingredient	verapamil 	consensus set annotator team	1430	1439	Active ingredient	aliskiren 	consensus set annotator team		1452	1461	Positive	Quantitative	2-fold increase in Cmax and AUC 	consensus set annotator team
156	Active ingredient	cyclosporine 	consensus set annotator team	1190	1202	Active ingredient	aliskiren 	consensus set annotator team		1214	1223	Positive	Quantitative	2.5-fold increase in Cmax and 5-fold increase in AUC 	consensus set annotator team
156	Active ingredient	lovastatin 	consensus set annotator team	1648	1658	Active ingredient	aliskiren 	consensus set annotator team		1833	1842	Negative	Qualitative	did not result in clinically significant increases in aliskiren exposure 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2306	2315	Active ingredient	ramipril 	consensus set annotator team		2459	2467	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2306	2315	Active ingredient	hydrochlorothiazide 	consensus set annotator team		2471	2490	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2024	2033	Active ingredient	furosemide 	consensus set annotator team		2058	2068	Positive	Quantitative	AUC and Cmax of furosemide were reduced by about 30% and 50 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2306	2315	Active ingredient	lovastatin 	consensus set annotator team		2369	2379	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2306	2315	Active ingredient	digoxin 	consensus set annotator team		2381	2388	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
156	Active ingredient	aliskiren 	consensus set annotator team	2306	2315	Active ingredient	valsartan 	consensus set annotator team		2390	2399	Negative	Qualitative	did not significantly affect the pharmacokinetics 	consensus set annotator team
156	Active ingredient	atorvastatin 	consensus set annotator team	543	555	Active ingredient	aliskiren 	consensus set annotator team		592	601	Positive	Quantitative	50% increase in aliskiren Cmax and AUC 	consensus set annotator team
158	Active ingredient	propafenone 	consensus set annotator team	486	497	Active ingredient	mexiletine 	consensus set annotator team		528	538	Negative	Qualitative	did not alter the kinetics 	consensus set annotator team
158	Active ingredient	fluvoxamine 	consensus set annotator team	348	359	Active ingredient	mexiletine 	consensus set annotator team		282	292	Positive	Quantitative	decreased by 38% 	consensus set annotator team
158	Active ingredient	propafenone 	consensus set annotator team	486	497	Active ingredient	mexiletine 	consensus set annotator team		613	623	Positive	Quantitative	clearance of mexiletine in the extensive metabolizer phenotype decreased by about 70% 	consensus set annotator team
158	Active ingredient	mexiletine 	consensus set annotator team	891	901	Active ingredient	propafenone 	consensus set annotator team		816	827	Negative	Qualitative	pharmacokinetics of propafenone were unaffected 	consensus set annotator team
159	Active ingredient	Mexiletine 	consensus set annotator team	0	10	Active ingredient	digoxin 	consensus set annotator team		32	39	Negative	Qualitative	does not alter serum digoxin levels 	consensus set annotator team
159	Active ingredient	magnesium 	consensus set annotator team	51	60	Active ingredient	digoxin 	consensus set annotator team		205	212	Positive	Qualitative	been reported to lower serum digoxin levels 	consensus set annotator team
159	Active ingredient	aluminum 	consensus set annotator team	61	69	Active ingredient	digoxin 	consensus set annotator team		205	212	Positive	Qualitative	been reported to lower serum digoxin levels 	consensus set annotator team
161	Active ingredient	nelfinavir 	consensus set annotator team	20	30	Active ingredient	azithromycin 	consensus set annotator team		74	86	Positive	Qualitative	increased azithromycin serum concentrations 	consensus set annotator team
163	Active ingredient	acyclovir 	consensus set annotator team	102	111	Active ingredient	meperidine 	consensus set annotator team		36	46	Positive	Qualitative	Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased 	consensus set annotator team
163	Active ingredient	acyclovir 	consensus set annotator team	102	111	Metabolite	normeperidine 	consensus set annotator team	meperidine 	67	80	Positive	Qualitative	Plasma concentrations of meperidine and its metabolite, normeperidine, may be increased 	consensus set annotator team
164	Active ingredient	Cimetidine 	consensus set annotator team	12	22	Active ingredient	meperidine 	consensus set annotator team		75	85	Positive	Qualitative	reduced the clearance and volume of distribution 	consensus set annotator team
164	Active ingredient	Cimetidine 	consensus set annotator team	12	22	Metabolite	normeperidine 	consensus set annotator team	meperidine 	128	141	Positive	Qualitative	reduced the clearance and volume of distribution 	consensus set annotator team
166	Active ingredient	Penicillin 	consensus set annotator team	0	10	Active ingredient	methotrexate 	consensus set annotator team		46	58	Positive	Qualitative	increased serum concentrations 	consensus set annotator team
168	Active ingredient	Clonazepam 	consensus set annotator team	61	71	Active ingredient	carbamazepine 	consensus set annotator team		132	145	Negative	Qualitative	does not appear to alter the pharmacokinetics 	consensus set annotator team
168	Active ingredient	Clonazepam 	consensus set annotator team	61	71	Active ingredient	phenytoin 	consensus set annotator team		121	130	Negative	Qualitative	does not appear to alter the pharmacokinetics 	consensus set annotator team
168	Active ingredient	Clonazepam 	consensus set annotator team	61	71	Active ingredient	phenobarbital 	consensus set annotator team		149	162	Negative	Qualitative	does not appear to alter the pharmacokinetics 	consensus set annotator team
168	Active ingredient	Clonazepam 	consensus set annotator team	61	71	Active ingredient	carbamazepine 	consensus set annotator team		132	145	Negative	Qualitative	does not appear to alter the pharmacokinetics 	consensus set annotator team
170	Active ingredient	cholestyramine 	consensus set annotator team	666	680	Active ingredient	hydrochlorothiazide 	consensus set annotator team		711	730	Positive	Quantitative	reduce its absorption from the gastrointestinal tract by up to 85% and 43 	consensus set annotator team
170	Active ingredient	colestipol 	consensus set annotator team	684	694	Active ingredient	hydrochlorothiazide 	consensus set annotator team		711	730	Positive	Quantitative	reduce its absorption from the gastrointestinal tract by up to 85% and 43 	consensus set annotator team
170	Drug product	AVALIDE 	consensus set annotator team	1403	1410	Active ingredient	lithium 	consensus set annotator team		1264	1271	Positive	Qualitative	reduce the renal clearance of lithium 	consensus set annotator team
171	Active ingredient	hydrochlorothiazide 	consensus set annotator team	8618	8637	Active ingredient	irbesartan 	consensus set annotator team		8655	8665	Negative	Qualitative	had no effect on irbesartan pharmacokinetics 	consensus set annotator team
171	Active ingredient	irbesartan 	consensus set annotator team	8959	8969	Active ingredient	warfarin 	consensus set annotator team		8916	8924	Negative	Qualitative	had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics 	consensus set annotator team
171	Active ingredient	nifedipine 	consensus set annotator team	8604	8614	Active ingredient	irbesartan 	consensus set annotator team		8655	8665	Negative	Qualitative	had no effect on irbesartan pharmacokinetics 	consensus set annotator team
171	Active ingredient	hydrochlorothiazide 	consensus set annotator team	9191	9210	Active ingredient	irbesartan 	consensus set annotator team		9125	9135	Negative	Qualitative	The pharmacokinetics of irbesartan were not affected 	consensus set annotator team
171	Active ingredient	nifedipine 	consensus set annotator team	9177	9187	Active ingredient	irbesartan 	consensus set annotator team		9125	9135	Negative	Qualitative	The pharmacokinetics of irbesartan were not affected 	consensus set annotator team
171	Active ingredient	irbesartan 	consensus set annotator team	8959	8969	Active ingredient	digoxin 	consensus set annotator team		8950	8957	Negative	Qualitative	had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics 	consensus set annotator team
172	Active ingredient	clarithromycin 	consensus set annotator team	816	830	Drug product	LIPITOR 	consensus set annotator team		797	804	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	lopinavir 	consensus set annotator team	1329	1338	Drug product	LIPITOR 	consensus set annotator team		1241	1248	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	ritonavir 	consensus set annotator team	1260	1269	Drug product	LIPITOR 	consensus set annotator team		1241	1248	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	saquinavir 	consensus set annotator team	1275	1285	Drug product	LIPITOR 	consensus set annotator team		1241	1248	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Drug product	LIPITOR 	consensus set annotator team	3360	3367	Active ingredient	digoxin 	consensus set annotator team		3372	3379	Positive	Quantitative	concentrations increased by approximately 20% 	consensus set annotator team
172	Active ingredient	rifampin 	consensus set annotator team	2958	2966	Drug product	LIPITOR 	consensus set annotator team		2895	2902	Positive	Qualitative	can lead to variable reductions in plasma concentrations 	consensus set annotator team
172	Active ingredient	efavirenz 	consensus set annotator team	2947	2956	Drug product	LIPITOR 	consensus set annotator team		2895	2902	Positive	Qualitative	can lead to variable reductions in plasma concentrations 	consensus set annotator team
172	Active ingredient	rifampin 	consensus set annotator team	3226	3234	Active ingredient	atorvastatin 	consensus set annotator team		3287	3299	Positive	Qualitative	significant reduction in atorvastatin plasma concentrations 	consensus set annotator team
172	Active ingredient	cyclosporine 	consensus set annotator team	2537	2549	Active ingredient	Atorvastatin 	consensus set annotator team		2439	2451	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	itraconazole 	consensus set annotator team	1778	1790	Active ingredient	Atorvastatin 	consensus set annotator team		1680	1692	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	ritonavir 	consensus set annotator team	1344	1353	Active ingredient	Atorvastatin 	consensus set annotator team		1161	1173	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	lopinavir 	consensus set annotator team	1329	1338	Active ingredient	Atorvastatin 	consensus set annotator team		1161	1173	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	saquinavir 	consensus set annotator team	1275	1285	Active ingredient	Atorvastatin 	consensus set annotator team		1161	1173	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	ritonavir 	consensus set annotator team	1260	1269	Active ingredient	Atorvastatin 	consensus set annotator team		1161	1173	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Active ingredient	clarithromycin 	consensus set annotator team	816	830	Active ingredient	Atorvastatin 	consensus set annotator team		717	729	Positive	Qualitative	AUC was significantly increased 	consensus set annotator team
172	Drug product	LIPITOR 	consensus set annotator team	3582	3589	Active ingredient	norethindrone 	consensus set annotator team		3641	3654	Positive	Qualitative	increased AUC 	consensus set annotator team
172	Drug product	LIPITOR 	consensus set annotator team	3582	3589	Active ingredient	ethinyl estradiol 	consensus set annotator team		3659	3676	Positive	Qualitative	increased AUC 	consensus set annotator team
174	Active ingredient	rifampin 	consensus set annotator team	140	148	Active ingredient	tacrolimus 	consensus set annotator team		61	71	Positive	Quantitative	decrease in tacrolimus oral bioavailability (14?6% vs. 7?3%) 	consensus set annotator team
174	Active ingredient	rifampin 	consensus set annotator team	307	315	Active ingredient	tacrolimus 	consensus set annotator team		223	233	Positive	Quantitative	increase in tacrolimus clearance (0.036?0.008 L/hr/kg vs. 0.053?0.010 L/hr/kg 	consensus set annotator team
175	Active ingredient	Tacrolimus 	consensus set annotator team	747	757	Active ingredient	phenytoin 	consensus set annotator team		812	821	Positive	Qualitative	may affect the pharmacokinetics of other drugs (e.g., phenytoin) and increase their concentration 	consensus set annotator team
175	Active ingredient	nelfinavir 	consensus set annotator team	369	379	Active ingredient	tacrolimus 	consensus set annotator team		353	363	Positive	Qualitative	increased blood concentrations 	consensus set annotator team
177	Active ingredient	cimetidine 	consensus set annotator team	334	344	Active ingredient	diazepam 	consensus set annotator team		226	234	Positive	Qualitative	influence the pharmacokinetics 	consensus set annotator team
177	Active ingredient	fluoxetine 	consensus set annotator team	373	383	Active ingredient	diazepam 	consensus set annotator team		226	234	Positive	Qualitative	influence the pharmacokinetics 	consensus set annotator team
177	Active ingredient	fluvoxamine 	consensus set annotator team	360	371	Active ingredient	diazepam 	consensus set annotator team		226	234	Positive	Qualitative	influence the pharmacokinetics 	consensus set annotator team
177	Active ingredient	ketoconazole 	consensus set annotator team	346	358	Active ingredient	diazepam 	consensus set annotator team		226	234	Positive	Qualitative	influence the pharmacokinetics 	consensus set annotator team
177	Active ingredient	omeprazole 	consensus set annotator team	389	399	Active ingredient	diazepam 	consensus set annotator team		226	234	Positive	Qualitative	influence the pharmacokinetics 	consensus set annotator team
179	Active ingredient	Isoniazid 	consensus set annotator team	15	24	Active ingredient	carbamazepine 	consensus set annotator team		60	73	Positive	Qualitative	increase its serum levels 	consensus set annotator team
181	Drug product	oncovin 	consensus set annotator team	4041	4048	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Drug product	adriamycin 	consensus set annotator team	4101	4111	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	6500	6509	Active ingredient	lithium 	consensus set annotator team		6510	6517	Negative	Qualitative	increase in serum lithium levels 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	6125	6134	Active ingredient	carbamazepine 	consensus set annotator team		6156	6169	Positive	Qualitative	increase carbamazepine concentrations 	consensus set annotator team
181	Active ingredient	Phenobarbital 	consensus set annotator team	7467	7480	Active ingredient	verapamil 	consensus set annotator team		7502	7511	Positive	Qualitative	may increase verapamil clearance 	consensus set annotator team
181	Active ingredient	erythromycin 	consensus set annotator team	257	269	Active ingredient	verapamil 	consensus set annotator team		320	329	Positive	Qualitative	causing elevation of plasma levels 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	6323	6332	Active ingredient	cyclosporine 	consensus set annotator team		6370	6382	Positive	Qualitative	may increase serum levels 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	6500	6509	Active ingredient	lithium 	consensus set annotator team		6572	6579	Positive	Qualitative	increase in serum lithium levels 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	4186	4195	Active ingredient	paclitaxel 	consensus set annotator team		4226	4236	Positive	Qualitative	can decrease the clearance 	consensus set annotator team
181	Active ingredient	cisplatin 	consensus set annotator team	4113	4122	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	adriamycin 	consensus set annotator team	4101	4111	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	4778	4787	Active ingredient	quinidine 	consensus set annotator team		4754	4763	Positive	Qualitative	increased quinidine levels 	consensus set annotator team
181	Active ingredient	oncovin 	consensus set annotator team	4041	4048	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	procarbazine 	consensus set annotator team	4050	4062	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	cyclophosphamide 	consensus set annotator team	4023	4039	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	vindesine 	consensus set annotator team	4090	4099	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	prednisone 	consensus set annotator team	4064	4074	Active ingredient	verapamil 	consensus set annotator team		3991	4000	Positive	Qualitative	absorption of verapamil can be reduced 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	3285	3294	Active ingredient	ethanol 	consensus set annotator team		3335	3342	Positive	Qualitative	inhibit ethanol elimination resulting in elevated blood ethanol concentrations 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	2778	2787	Active ingredient	digitoxin 	consensus set annotator team		2848	2857	Positive	Quantitative	reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	3930	3939	Active ingredient	doxorubicin 	consensus set annotator team		3953	3964	Positive	Qualitative	increase doxorubicin levels 	consensus set annotator team
181	Active ingredient	Verapamil 	consensus set annotator team	7633	7642	Active ingredient	theophylline 	consensus set annotator team		7703	7715	Positive	Qualitative	increase the plasma levels 	consensus set annotator team
181	Active ingredient	cimetidine 	consensus set annotator team	7759	7769	Active ingredient	verapamil 	consensus set annotator team		7933	7942	Positive	Qualitative	clearance of verapamil was either reduced or unchanged 	consensus set annotator team
181	Active ingredient	cimetidine 	consensus set annotator team	7759	7769	Active ingredient	verapamil 	consensus set annotator team		7933	7942	Negative	Qualitative	clearance of verapamil was either reduced or unchanged 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	6613	6622	Active ingredient	lithium 	consensus set annotator team		6666	6673	Positive	Qualitative	lowering of serum lithium levels 	consensus set annotator team
181	Active ingredient	rifampin 	consensus set annotator team	7552	7560	Active ingredient	verapamil 	consensus set annotator team		7586	7595	Positive	Qualitative	reduce oral verapamil bioavailability 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	2529	2538	Active ingredient	digoxin 	consensus set annotator team		2568	2575	Positive	Quantitative	increase serum digoxin levels by 50% to 75 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	2278	2287	Active ingredient	metoprolol 	consensus set annotator team		2171	2181	Positive	Qualitative	decrease in metoprolol and propranolol clearance 	consensus set annotator team
181	Active ingredient	verapamil 	consensus set annotator team	2278	2287	Active ingredient	propranolol 	consensus set annotator team		2186	2197	Positive	Qualitative	decrease in metoprolol and propranolol clearance 	consensus set annotator team
181	Active ingredient	rifampin 	consensus set annotator team	527	535	Active ingredient	verapamil 	consensus set annotator team		580	589	Positive	Qualitative	lowering of plasma levels 	consensus set annotator team
181	Active ingredient	ritonavir 	consensus set annotator team	271	280	Active ingredient	verapamil 	consensus set annotator team		320	329	Positive	Qualitative	causing elevation of plasma levels 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	1882	1894	Active ingredient	theophylline 	consensus set annotator team		1824	1836	Positive	Quantitative	increase (10%) in the clearance 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	672	684	Active ingredient	ketoconazole 	consensus set annotator team		890	902	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	672	684	Active ingredient	iron 	consensus set annotator team		878	882	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	1038	1050	Active ingredient	warfarin 	consensus set annotator team		1128	1136	Negative	Qualitative	did not affect the pharmacokinetics 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	1603	1615	Active ingredient	tacrolimus 	consensus set annotator team		1620	1630	Positive	Qualitative	may increase whole blood levels 	consensus set annotator team
183	Active ingredient	Lansoprazole 	consensus set annotator team	162	174	Active ingredient	atazanavir 	consensus set annotator team		310	320	Positive	Qualitative	decrease the systemic concentrations 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	672	684	Active ingredient	ampicillin 	consensus set annotator team		850	860	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
183	Active ingredient	lansoprazole 	consensus set annotator team	672	684	Active ingredient	digoxin 	consensus set annotator team		869	876	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	17312	17324	Active ingredient	methotrexate 	consensus set annotator team		17403	17415	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	diazepam 	consensus set annotator team		15134	15142	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	prednisone 	consensus set annotator team		15122	15132	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	clarithromycin 	consensus set annotator team		15147	15161	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	antipyrine 	consensus set annotator team		15061	15071	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	propranolol 	consensus set annotator team		15109	15120	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	ibuprofen 	consensus set annotator team		15087	15096	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	phenytoin 	consensus set annotator team		15098	15107	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14590	14602	Active ingredient	digoxin 	consensus set annotator team		14768	14775	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	warfarin 	consensus set annotator team		15051	15059	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	16566	16578	Active ingredient	warfarin 	consensus set annotator team		16466	16474	Negative	Qualitative	neither the pharmacokinetics of warfarin enantiomers nor prothrombin time were affected 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	17312	17324	Active ingredient	methotrexate 	consensus set annotator team		17224	17236	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
184	Active ingredient	Lansoprazole 	consensus set annotator team	17581	17593	Active ingredient	amoxicillin 	consensus set annotator team		17690	17701	Negative	Qualitative	no clinically significant interaction 	consensus set annotator team
184	Active ingredient	naproxen 	consensus set annotator team	17280	17288	Active ingredient	methotrexate 	consensus set annotator team		17403	17415	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
184	Active ingredient	naproxen 	consensus set annotator team	17280	17288	Metabolite	7-hydroxymethotrexate 	consensus set annotator team	methotrexate 	17420	17441	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	17312	17324	Metabolite	7-hydroxymethotrexate 	consensus set annotator team	methotrexate 	17420	17441	Negative	Qualitative	had no effect on the pharmacokinetics 	consensus set annotator team
184	Active ingredient	sucralfate 	consensus set annotator team	17871	17881	Active ingredient	lansoprazole 	consensus set annotator team		17759	17771	Positive	Quantitative	absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16% 	consensus set annotator team
184	Active ingredient	sucralfate 	consensus set annotator team	17871	17881	Active ingredient	omeprazole 	consensus set annotator team		17807	17817	Positive	Quantitative	absorption of the proton pump inhibitors was delayed and their bioavailability was reduced by 17% and 16% 	consensus set annotator team
184	Active ingredient	zidovudine 	consensus set annotator team	15419	15431	Active ingredient	atazanavir 	consensus set annotator team		15539	15549	Positive	Qualitative	substantially decreases the systemic concentrations 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	15870	15882	Active ingredient	theophylline 	consensus set annotator team		16018	16030	Positive	Quantitative	a minor increase (10%) in the clearance 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	clarithromycin 	consensus set annotator team		15147	15161	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	propranolol 	consensus set annotator team		15109	15120	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	diazepam 	consensus set annotator team		15134	15142	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	prednisone 	consensus set annotator team		15122	15132	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	ibuprofen 	consensus set annotator team		15087	15096	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	phenytoin 	consensus set annotator team		15098	15107	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	warfarin 	consensus set annotator team		15051	15059	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	antipyrine 	consensus set annotator team		15061	15071	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14920	14932	Active ingredient	indomethacin 	consensus set annotator team		15073	15085	Negative	Qualitative	does not have clinically significant interactions 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14590	14602	Active ingredient	iron 	consensus set annotator team		14756	14760	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14590	14602	Active ingredient	ketoconazole 	consensus set annotator team		14723	14735	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
184	Active ingredient	lansoprazole 	consensus set annotator team	14590	14602	Active ingredient	ampicillin 	consensus set annotator team		14737	14747	Positive	Qualitative	may interfere with the absorption 	consensus set annotator team
185	Active ingredient	simvastatin 	consensus set annotator team	2157	2168	Active ingredient	digoxin 	consensus set annotator team		2144	2151	Positive	Qualitative	slight elevation in digoxin concentrations 	consensus set annotator team
186	Active ingredient	simvastatin 	consensus set annotator team	3928	3939	Active ingredient	erythromycin 	consensus set annotator team		4065	4077	Negative	Qualitative	had no effect on the metabolism 	consensus set annotator team
186	Active ingredient	cyclosporine 	consensus set annotator team	3444	3456	Active ingredient	simvastatin 	consensus set annotator team		3528	3539	Positive	Qualitative	increase the AUC 	consensus set annotator team
186	Active ingredient	simvastatin 	consensus set annotator team	3928	3939	Active ingredient	midazolam 	consensus set annotator team		4051	4060	Negative	Quantitative	no effect on the metabolism 	consensus set annotator team
186	Active ingredient	simvastatin 	consensus set annotator team	3928	3939	Active ingredient	erythromycin 	consensus set annotator team		4065	4077	Negative	Quantitative	no effect on the metabolism 	consensus set annotator team
186	Active ingredient	simvastatin 	consensus set annotator team	4261	4272	Active ingredient	digoxin 	consensus set annotator team		4363	4370	Positive	Quantitative	increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	desipramine 	consensus set annotator team		2596	2607	Negative	Qualitative	does not interact 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	nortriptyline 	consensus set annotator team		2581	2594	Negative	Qualitative	does not interact 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2699	2706	Active ingredient	methadone 	consensus set annotator team		2731	2740	Negative	Qualitative	no clinically significant drug interactions were observed 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	metoprolol 	consensus set annotator team		2609	2619	Negative	Qualitative	does not interact 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	dapsone 	consensus set annotator team		2453	2460	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	trimethoprim 	consensus set annotator team		2462	2474	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	pravastatin 	consensus set annotator team		2440	2451	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	azithromycin 	consensus set annotator team		2493	2505	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	sulfamethoxazole 	consensus set annotator team		2475	2491	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	nortriptyline 	consensus set annotator team		2581	2594	Negative	Qualitative	does not interact 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	erythromycin 	consensus set annotator team		2510	2522	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	metoprolol 	consensus set annotator team		2609	2619	Negative	Qualitative	does not interact 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2524	2531	Active ingredient	desipramine 	consensus set annotator team		2596	2607	Negative	Qualitative	does not interact 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2699	2706	Active ingredient	acetaminophen 	consensus set annotator team		2755	2768	Negative	Qualitative	no clinically significant drug interactions were observed 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2699	2706	Active ingredient	fluconazole 	consensus set annotator team		2742	2753	Negative	Qualitative	no clinically significant drug interactions were observed 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2699	2706	Active ingredient	methadone 	consensus set annotator team		2731	2740	Negative	Qualitative	no clinically significant drug interactions were observed 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	2699	2706	Active ingredient	atenolol 	consensus set annotator team		2773	2781	Negative	Qualitative	no clinically significant drug interactions were observed 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	466	473	Active ingredient	repaglinide 	consensus set annotator team		597	608	Positive	Qualitative	Caution should be used 	consensus set annotator team
187	Active ingredient	atazanavir 	consensus set annotator team	2403	2413	Active ingredient	fluvastatin 	consensus set annotator team		2427	2438	Negative	Qualitative	clinically significant drug interactions are not expected 	consensus set annotator team
187	Drug product	REYATAZ 	consensus set annotator team	466	473	Active ingredient	paclitaxel 	consensus set annotator team		585	595	Positive	Qualitative	Caution should be used 	consensus set annotator team
188	Active ingredient	atazanavir 	consensus set annotator team	1469	1479	Active ingredient	diltiazem 	consensus set annotator team		1502	1511	Positive	Quantitative	there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval 	consensus set annotator team
188	Active ingredient	atazanavir 	consensus set annotator team	1694	1704	Active ingredient	atenolol 	consensus set annotator team		1727	1735	Negative	Qualitative	no substantial additive effect 	consensus set annotator team
191	Active ingredient	fluvastatin 	consensus set annotator team	45	56	Active ingredient	itraconazole 	consensus set annotator team		69	81	Negative	Qualitative	does not affect plasma itraconazole or fluvastatin levels 	consensus set annotator team
191	Active ingredient	itraconazole 	consensus set annotator team	69	81	Active ingredient	fluvastatin 	consensus set annotator team		45	56	Negative	Qualitative	does not affect plasma itraconazole or fluvastatin levels 	consensus set annotator team
192	Active ingredient	Erythromycin 	consensus set annotator team	15	27	Active ingredient	fluvastatin 	consensus set annotator team		95	106	Negative	Qualitative	did not affect steady-state plasma levels 	consensus set annotator team
194	Active ingredient	quinidine 	consensus set annotator team	1724	1733	Active ingredient	propafenone 	consensus set annotator team		1775	1786	Positive	Quantitative	increased steady state concentrations of propafenone 3-fold 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		1901	1912	Positive	Quantitative	decreased the plasma concentrations of propafenone by 67% 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		2159	2170	Positive	Quantitative	a 50% decrease in propafenone plasma concentrations 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		2419	2430	Positive	Quantitative	Both the AUC and Cmax propafenone decreased by 84 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		1978	1989	Positive	Quantitative	concentrations of norpropafenone increased by 30 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		1978	1989	Positive	Quantitative	increased the AUC and Cmax of norpropafenone by 74 and 20 	consensus set annotator team
194	Active ingredient	rifampin 	consensus set annotator team	1888	1896	Active ingredient	propafenone 	consensus set annotator team		2419	2430	Positive	Quantitative	decrease in AUC and Cmax of 5OH-propafenone by 69 and 57% 	consensus set annotator team
194	Active ingredient	propafenone 	consensus set annotator team	2562	2573	Active ingredient	digoxin 	consensus set annotator team		2578	2585	Positive	Quantitative	increased steady-state serum digoxin exposure (AUC) in patients by 60 to 270% 	consensus set annotator team
194	Active ingredient	propafenone 	consensus set annotator team	2868	2879	Active ingredient	warfarin 	consensus set annotator team		2884	2892	Positive	Quantitative	increased warfarin plasma concentrations at steady state by 39% 	consensus set annotator team
194	Active ingredient	propafenone 	consensus set annotator team	3474	3485	Active ingredient	propranolol 	consensus set annotator team		3490	3501	Positive	Quantitative	increased propranolol plasma concentrations at steady state by 113% 	consensus set annotator team
194	Active ingredient	propafenone 	consensus set annotator team	3640	3651	Active ingredient	metoprolol 	consensus set annotator team		3624	3634	Positive	Quantitative	increased the metoprolol plasma concentrations at steady state by 100-400% 	consensus set annotator team
194	Active ingredient	propranolol 	consensus set annotator team	3815	3826	Active ingredient	propafenone 	consensus set annotator team		3752	3763	Negative	Qualitative	The pharmacokinetics of propafenone was not affected 	consensus set annotator team
194	Active ingredient	metoprolol 	consensus set annotator team	3830	3840	Active ingredient	propafenone 	consensus set annotator team		3867	3878	Negative	Qualitative	The pharmacokinetics of propafenone was not affected 	consensus set annotator team
194	Active ingredient	lidocaine 	consensus set annotator team	4101	4110	Active ingredient	propafenone 	consensus set annotator team		4086	4097	Negative	Qualitative	No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen 	consensus set annotator team
194	Active ingredient	ritonavir 	consensus set annotator team	115	124	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	paroxetine 	consensus set annotator team	103	113	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	desipramine 	consensus set annotator team	90	101	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	saquinavir 	consensus set annotator team	183	193	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	erythromycin 	consensus set annotator team	195	207	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	ritonavir 	consensus set annotator team	172	181	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	ketoconazole 	consensus set annotator team	158	170	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	sertraline 	consensus set annotator team	126	136	Active ingredient	propafenone 	consensus set annotator team		283	294	Positive	Qualitative	cause increased plasma levels 	consensus set annotator team
194	Active ingredient	quinidine 	consensus set annotator team	1421	1430	Active ingredient	propafenone 	consensus set annotator team		1487	1498	Positive	Quantitative	plasma concentrations increased by more that 2-fold for propafenone 	consensus set annotator team
194	Active ingredient	fluoxetine 	consensus set annotator team	1065	1075	Active ingredient	propafenone 	consensus set annotator team		1049	1060	Positive	Quantitative	increased the S propafenone Cmax and AUC by 39 and 50% and the R propafenone Cmax and AUC by 71 and 50% 	consensus set annotator team
194	Active ingredient	cimetidine 	consensus set annotator team	891	901	Active ingredient	propafenone 	consensus set annotator team		849	860	Positive	Quantitative	20% increase in steady-state plasma concentrations 	consensus set annotator team
194	Active ingredient	propafenone 	consensus set annotator team	4086	4097	Active ingredient	lidocaine 	consensus set annotator team		4101	4110	Negative	Qualitative	No significant effects on the pharmacokinetics of propafenone or lidocaine have been seen 	consensus set annotator team
197	Active ingredient	ribavirin 	consensus set annotator team	6728	6737	Active ingredient	stavudine 	consensus set annotator team		6763	6772	Negative	Qualitative	no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed 	consensus set annotator team
197	Active ingredient	ribavirin 	consensus set annotator team	6728	6737	Active ingredient	zidovudine 	consensus set annotator team		6786	6796	Negative	Qualitative	no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed 	consensus set annotator team
197	Active ingredient	ribavirin 	consensus set annotator team	6728	6737	Active ingredient	lamivudine 	consensus set annotator team		6742	6752	Negative	Qualitative	no pharmacokinetic (e.g., plasma concentrations or intracellular triphosphorylated active metabolite concentrations) or pharmacodynamic (e.g., loss of HIV-1/HCV virologic suppression) interaction was observed 	consensus set annotator team
197	Active ingredient	zidovudine 	consensus set annotator team	6138	6148	Active ingredient	phenytoin 	consensus set annotator team		6093	6102	Negative	Qualitative	no change in phenytoin kinetics 	consensus set annotator team
197	Active ingredient	phenytoin 	consensus set annotator team	6286	6295	Active ingredient	zidovudine 	consensus set annotator team		6299	6309	Positive	Quantitative	30% decrease in oral zidovudine clearance was observed 	consensus set annotator team
197	Active ingredient	zidovudine 	consensus set annotator team	5923	5933	Active ingredient	Phenytoin 	consensus set annotator team		5843	5852	Positive	Qualitative	plasma levels have been reported to be low 	consensus set annotator team
198	Active ingredient	methadone 	consensus set annotator team	66	75	Active ingredient	didanosine 	consensus set annotator team		114	124	Positive	Qualitative	decreased the AUC and peak levels 	consensus set annotator team
198	Active ingredient	methadone 	consensus set annotator team	66	75	Active ingredient	stavudine 	consensus set annotator team		129	138	Positive	Qualitative	decreased the AUC and peak levels 	consensus set annotator team
199	Active ingredient	methadone 	consensus set annotator team	52	61	Active ingredient	zidovudine 	consensus set annotator team		125	135	Positive	Qualitative	increased the area under the concentration-time curve (AUC) 	consensus set annotator team
200	Active ingredient	rifampin 	consensus set annotator team	82	90	Active ingredient	methadone 	consensus set annotator team		41	50	Positive	Qualitative	reduction in serum methadone levels 	consensus set annotator team
201	Active ingredient	phenytoin 	consensus set annotator team	86	95	Active ingredient	methadone 	consensus set annotator team		55	64	Positive	Quantitative	50% reduction in methadone exposure 	consensus set annotator team
202	Active ingredient	voriconazole 	consensus set annotator team	49	61	Active ingredient	methadone 	consensus set annotator team		147	156	Positive	Quantitative	Cmax and AUC of (S)-methadone increased by 65% and 103% 	consensus set annotator team
202	Active ingredient	voriconazole 	consensus set annotator team	49	61	Active ingredient	methadone 	consensus set annotator team		281	290	Positive	Quantitative	Cmax and AUC of (S)-methadone increased by 65% and 103% 	consensus set annotator team
203	Active ingredient	methadone 	consensus set annotator team	72	81	Active ingredient	desipramine 	consensus set annotator team		29	40	Positive	Qualitative	Blood levels of desipramine have increased 	consensus set annotator team
207	Active ingredient	clopidogrel 	consensus set annotator team	1465	1476	Active ingredient	warfarin 	consensus set annotator team		1532	1540	Negative	Qualitative	did not modify the pharmacokinetics 	consensus set annotator team
207	Active ingredient	omeprazole 	consensus set annotator team	597	607	Active ingredient	clopidogrel 	consensus set annotator team		696	707	Positive	Quantitative	exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5 	consensus set annotator team
207	Active ingredient	omeprazole 	consensus set annotator team	769	779	Drug product	Plavix 	consensus set annotator team		758	764	Positive	Quantitative	exposure to the active metabolite of clopidogrel was decreased by 46% (Day 1) and 42% (Day 5 	consensus set annotator team
